Roche 1 **PEGASYS®** 2 3 (peginterferon alfa-2a) 4 **Rx only** 5 Alpha interferons, including PEGASYS (peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and 6 7 infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently 8 severe or worsening signs or symptoms of these conditions. In many, but not all 9 cases, these disorders resolve after stopping PEGASYS therapy (see WARNINGS 10 11 and ADVERSE REACTIONS). Use with Ribavirin. Ribavirin, including COPEGUS[®], may cause birth defects 12 and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female 13 patients and in female partners of male patients. Ribavirin causes hemolytic anemia. 14 The anemia associated with ribavirin therapy may result in a worsening of cardiac 15 16 disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see COPEGUS Package Insert for additional information and other 17 18 WARNINGS).

19 **DESCRIPTION**

20 PEGASYS, peginterferon alfa-2a, is a covalent conjugate of recombinant alfa-2a interferon (approximate molecular weight [MW] 20,000 daltons) with a single branched 21. bis-monomethoxy polyethylene glycol (PEG) chain (approximate MW 40,000 daltons). 22 The PEG moiety is linked at a single site to the interferon alfa moiety via a stable amide 23 bond to lysine. Peginterferon alfa-2a has an approximate molecular weight of 60,000 24 daltons. Interferon alfa-2a is produced using recombinant DNA technology in which a 25 26 cloned human leukocyte interferon gene is inserted into and expressed in Escherichia 27 coli.

28 PEGASYS is supplied as an injectable solution in vials and prefilled syringes.

180 μ g/1.0 mL Vial: A vial contains approximately 1.2 mL of solution to deliver 1.0 mL of drug product. Subcutaneous (sc) administration of 1.0 mL delivers 180 μ g of drug product (expressed as the amount of interferon alfa-2a), 8.0 mg sodium chloride, 0.05 mg polysorbate 80, 10.0 mg benzyl alcohol, 2.62 mg sodium acetate trihydrate, and 0.05 mg acetic acid. The solution is colorless to light yellow and the pH is 6.0 ± 0.5.

180 μ g/0.5 mL Prefilled Syringe: Each syringe contains 0.6 mL of solution to deliver 0.5 mL of drug product. Subcutaneous (sc) administration of 0.5 mL delivers 180 μ g of drug product (expressed as the amount of interferon alfa-2a), 4.0 mg sodium chloride, 0.025 mg polysorbate 80, 5.0 mg benzyl alcohol, 1.3085 mg sodium acetate trihydrate, and 0.0231 mg acetic acid. The solution is colorless to light yellow and the pH is 6.0 ± 0.5.

1

40 CLINICAL PHARMACOLOGY

41 **Pharmacodynamics**

42 Interferons bind to specific receptors on the cell surface initiating intracellular signaling 43 via a complex cascade of protein-protein interactions leading to rapid activation of gene 44 transcription. Interferon-stimulated genes modulate many biological effects including the 45 inhibition of viral replication in infected cells, inhibition of cell proliferation and 46 immunomodulation. The clinical relevance of these in vitro activities is not known.

47 PEGASYS stimulates the production of effector proteins such as serum neopterin and 2',
48 5'-oligoadenylate synthetase.

49 **Pharmacokinetics**

50 Maximal serum concentrations (C_{max}) and AUC increased in a nonlinear dose related 51 manner following administration of 90 to 270 µg of PEGASYS. Maximal serum 52 concentrations (C_{max}) occur between 72 to 96 hours post-dose.

53 Week 48 mean trough concentrations (16 ng/mL; range 4 to 28) at 168 hours post-dose 54 are approximately 2-fold higher than week 1 mean trough concentrations (9 ng/mL; range 55 0 to 15). Steady-state serum levels are reached within 5 to 8 weeks of once weekly 56 dosing. The peak to trough ratio at week 48 is approximately 2. The mean systemic 57 clearance in healthy subjects given PEGASYS was 94 mL/h, which is approximately 100-fold lower than that for interferon alfa-2a (ROFERON[®]-A). The mean terminal half-58 59 life after sc dosing in patients with chronic hepatitis C was 80 hours (range 50 to 140 60 hours) compared to 5 hours (range 3.7 to 8.5 hours) for ROFERON-A.

61 **Special Populations**

62 Gender and Age

PEGASYS administration yielded similar pharmacokinetics in male and female healthy
subjects. The AUC was increased from 1295 to 1663 ng·h/mL in subjects older than 62
years taking 180 µg PEGASYS, but peak concentrations were similar (9 vs. 10 ng/mL) in
those older and younger than 62 years.

67 Pediatric Patients

In a population pharmacokinetics study, 14 children 2 to 8 years of age with CHC received PEGASYS based on their body surface area (BSA of the child x 180 μ g/1.73m²). The clearance of PEGASYS in children was nearly 4-fold lower compared to the clearance reported in adults.

72 Steady-state trough levels in children with the BSA-adjusted dosing were similar to 73 trough levels observed in adults with 180 µg fixed dosing. Time to reach the steady state 74 in children is approximately 12 weeks, whereas in adults, steady state is reached within 5 75 to 8 weeks. In these children receiving the BSA adjusted dose, the mean exposure (AUC) 76 during the dosing interval is predicted to be 25% to 70% higher than that observed in 77 adults receiving 180 µg fixed dosing. The safety and effectiveness of PEGASYS in 78 patients below the age of 18 years have not been established (see **PRECAUTIONS**: 79 Pediatric Use).

80 Renal Dysfunction

In patients with end stage renal disease undergoing hemodialysis, there is a 25% to 45%
 reduction in PEGASYS clearance (see **PRECAUTIONS: Renal Impairment**).

The pharmacokinetics of ribavirin following administration of COPEGUS have not been studied in patients with renal impairment and there are limited data from clinical trials on administration of COPEGUS in patients with creatinine clearance <50 mL/min. Therefore, patients with creatinine clearance <50 mL/min should not be treated with COPEGUS (see WARNINGS and DOSAGE AND ADMINISTRATION).

88 Effect of Food on Absorption of Ribavirin

Bioavailability of a single oral dose of ribavirin was increased by co-administration with a high-fat meal. The absorption was slowed (T_{max} was doubled) and the AUC_{0-192h} and C_{max} increased by 42% and 66%, respectively, when COPEGUS was taken with a high-

92 fat meal compared with fasting conditions (see **DOSAGE AND ADMINISTRATION**).

93 **Drug Interactions**

94 Nucleoside Analogues

In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n=18), stavudine (n=10), or zidovudine (n=6) were co-administered as part of a multi-drug regimen to HCV/HIV coinfected patients (see **PRECAUTIONS: Drug Interactions).**

In vitro, didanosine or its active metabolite (dideoxyadenosine 5'-triphosphate) is
 increased when didanosine is co-administered with ribavirin (see PRECAUTIONS:
 Drug Interactions).

105 Drugs Metabolized by Cytochrome P450

There was no effect on the pharmacokinetics of representative drugs metabolized by CYP2C9, CYP 2C19, CYP 2D6 or CYP 3A4.

Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated
with an inhibition of P450 1A2 and a 25% increase in theophylline AUC (see
PRECAUTIONS: Drug Interactions).

111 Methadone

112 The pharmacokinetics of concomitant administration of methadone and PEGASYS were 113 evaluated in 24 PEGASYS naive chronic hepatitis C (CHC) patients (15 male, 9 female) 114 who received 180 µg PEGASYS subcutaneously weekly. All patients were on stable 115 methadone maintenance therapy (median dose 95 mg, range 30 mg to 150 mg) prior to 116 receiving PEGASYS. Mean methadone PK parameters were 10% to 15% higher after 4 117 weeks of PEGASYS treatment as compared to baseline (see PRECAUTIONS: Drug 118 Interactions). Methadone did not significantly alter the PK of PEGASYS as compared to 119 a PK study of 6 chronic hepatitis C patients not receiving methadone.

120 CLINICAL STUDIES

121 Chronic Hepatitis C Studies 1, 2, and 3: PEGASYS Monotherapy

122 The safety and effectiveness of PEGASYS for the treatment of hepatitis C virus infection 123 were assessed in three randomized, open-label, active-controlled clinical studies. All 124 patients were adults, had compensated liver disease, detectable hepatitis C virus (HCV). 125 liver biopsy diagnosis of chronic hepatitis, and were previously untreated with interferon. 126 All patients received therapy by sc injection for 48 weeks, and were followed for an 127 additional 24 weeks to assess the durability of response. In studies 1 and 2, approximately 128 20% of subjects had cirrhosis or bridging fibrosis. Study 3 enrolled patients with a 129 histological diagnosis of cirrhosis (78%) or bridging fibrosis (22%).

In Study 1 (n=630), patients received either ROFERON-A (interferon alfa-2a) 3 MIU
three times/week (tiw), PEGASYS 135 µg once each week (qw) or PEGASYS 180 µg
qw. In Study 2 (n=526), patients received either ROFERON-A 6 MIU tiw for 12 weeks
followed by 3 MIU tiw for 36 weeks or PEGASYS 180 µg qw. In Study 3 (n=269),
patients received ROFERON-A 3 MIU tiw, PEGASYS 90 µg qw or PEGASYS 180 µg
once each week.

In all three studies, treatment with PEGASYS 180 μ g resulted in significantly more patients who experienced a sustained response (defined as undetectable HCV RNA [<50 IU/mL] using the COBAS AMPLICOR[®] HCV Test, version 2.0 and normalization of ALT on or after study week 68) compared to treatment with ROFERON-A. In Study 1, response to PEGASYS 135 μ g was not different from response to 180 μ g. In Study 3, response to PEGASYS 90 μ g was intermediate between PEGASYS 180 μ g and ROFERON-A.

		Study 1			Study 2		Study 3		
	ROFERON-A 3 MIU (N=207)	Редазуз 180 µg (N=208)	DIFF* (95% CI)	ROFERON-A 6/3 MIU (N=261)	Редазуз 180 µg (N=265)	DIFF * (95% CI)	Roferon-A 3 MIU (N=86)	Редазуз 180 µg (N=87)	DIFF * (95% CI)
Combined Virologic and Biologic Sustained Response	11%	24%	13 (6, 20)	17%	35%	18 (11, 25)	7%	23%	16 (6, 26)
Sustained Virologic Response	11%	26%	15 (8, 23)	19%	38%	19 (11, 26)	8%	30%	22 (11, 33

 143
 Table 1
 Sustained Response to Monotherapy Treatment

144 *Percent difference between PEGASYS and ROFERON-A treatment.

145

146 Matched pre- and post-treatment liver biopsies were obtained in approximately 70% of

patients. Similar modest reductions in inflammation compared to baseline were observedin all treatment groups.

149 Of the patients who did not demonstrate either undetectable HCV RNA or at least a

150 2log₁₀ drop in HCV RNA titer from baseline by 12 weeks of PEGASYS 180 μg therapy,

151 2% (3/156) achieved a sustained virologic response (see DOSAGE AND
 152 ADMINISTRATION).

Averaged over Study 1, Study 2, and Study 3, response rates to PEGASYS were 23% among patients with viral genotype 1 and 48% in patients with other viral genotypes. The treatment response rates were similar in men and women.

Chronic Hepatitis C Studies 4 and 5: PEGASYS/COPEGUS Combination Therapy

The safety and effectiveness of PEGASYS in combination with COPEGUS for the treatment of hepatitis C virus infection were assessed in two randomized controlled clinical trials. All patients were adults, had compensated liver disease, detectable hepatitis C virus, liver biopsy diagnosis of chronic hepatitis, and were previously untreated with interferon. Approximately 20% of patients in both studies had compensated cirrhosis (Child-Pugh class A). Patients coinfected with HIV were excluded from these studies.

In Study 4, patients were randomized to receive either PEGASYS 180 µg sc once weekly 164 (qw) with an oral placebo, PEGASYS 180 µg qw with COPEGUS 1000 mg po (body 165 weight <75 kg) or 1200 mg po (body weight ≥75 kg) or REBETRON[®] (interferon alfa-2b 166 3 MIU sc tiw plus ribavirin 1000 mg or 1200 mg po). All patients received 48 weeks of 167 therapy followed by 24 weeks of treatment-free follow-up. COPEGUS or placebo 168 169 treatment assignment was blinded. Sustained virological response was defined as 170 undetectable (<50 IU/mL) HCV RNA on or after study week 68. PEGASYS in combination with COPEGUS resulted in a higher SVR compared to PEGASYS alone or 171 interferon alfa-2b and ribavirin (Table 2). In all treatment arms, patients with viral 172 173 genotype 1, regardless of viral load, had a lower response rate.

174Table 2Sustained Virologic Response to Combination Therapy175(Study 4)

	Interferon alfa-2b +	PEGASYS +	PEGASYS +
	Ribavirin 1000 mg or 1200 mg	Placebo	COPEGUS 1000 mg or 1200 mg
All patients	197/444 (44%)*	65/224 (29%)	241/453 (53%)*
Genotype 1	103/285 (36%)	29/145 (20%)	132/298 (44%)
Genotypes 2-6	94/159 (59%)	36/79 (46%)	109/155 (70%)

*Difference in overall treatment response (PEGASYS/COPEGUS – Interferon alfa-2b/ribavirin) was 9%
 (95% CI 2.3, 15.3).

178

In Study 5 (see Table 3), all patients received PEGASYS 180 μ g sc qw and were randomized to treatment for either 24 or 48 weeks and to a COPEGUS dose of either 800 mg or 1000 mg/1200 mg (for body weight <75 kg / ≥75 kg). Assignment to the four treatment arms was stratified by viral genotype and baseline HCV viral titer. Patients with genotype 1 and high viral titer (defined as >2 x 10⁶ HCV RNA copies/mL serum)

184 were preferentially assigned to treatment for 48 weeks.

185 HCV Genotypes

HCV 1 and 4 – Irrespective of baseline viral titer, treatment for 48 weeks with
PEGASYS and 1000 mg or 1200 mg of COPEGUS resulted in higher SVR (defined as
undetectable HCV RNA at the end of the 24-week treatment-free follow-up period)
compared to shorter treatment (24 weeks) and/or 800 mg COPEGUS.

HCV 2 and 3 – Irrespective of baseline viral titer, treatment for 24 weeks with
PEGASYS and 800 mg of COPEGUS resulted in a similar SVR compared to longer
treatment (48 weeks) and/or 1000 mg or 1200 mg of COPEGUS (see Table 3).

193 The numbers of patients with genotype 5 and 6 were too few to allow for meaningful 194 assessment.

195Table 3Sustained Virologic Response as a Function of Genotype196(Study 5)

	24 Wee	ks Treatment	48 Weeks Treatment	
	PEGASYS +	PEGASYS +	PEGASYS +	PEGASYS +
	COPEGUS 800 mg	COPEGUS 1000 mg or 1200 mg*	COPEGUS 800 mg	COPEGUS 1000 mg or 1200 mg*
	(N=207)	(N=280)	(N=361)	(N=436)
Genotype 1	29/101 (29%)	48/118 (41%)	99/250 (40%)	138/271 (51%)
Genotypes 2, 3	79/96 (82%)	116/144 (81%)	75/99 (76%)	117/153 (76%)
Genotype 4	0/5 (0%)	7/12 (58%)	5/8 (63%)	9/11 (82%)

197 *1000 mg for body weight <75 kg; 1200 mg for body weight \ge 75 kg.

198 Other Treatment Response Predictors

199 Treatment response rates are lower in patients with poor prognostic factors receiving 200 pegylated interferon alpha therapy. In studies 4 and 5, treatment response rates were 201 lower in patients older than 40 years (50% vs. 66%), in patients with cirrhosis (47% vs. 202 59%), in patients weighing over 85 kg (49% vs. 60%), and in patients with genotype 1 203 with high vs. low viral load (43% vs. 56%). African-American patients had lower 204 response rates compared to Caucasians.

Paired liver biopsies were performed on approximately 20% of patients in studies 4 and
5. Modest reductions in inflammation compared to baseline were seen in all treatment
groups.

In studies 4 and 5, lack of early virologic response by 12 weeks (defined as HCV RNA undetectable or $>2\log_{10}$ lower than baseline) was grounds for discontinuation of treatment. Of patients who lacked an early viral response by 12 weeks and completed a recommended course of therapy despite a protocol-defined option to discontinue therapy, 5/39 (13%) achieved an SVR. Of patients who lacked an early viral response by 24 weeks, 19 completed a full course of therapy and none achieved an SVR.

214 Chronic Hepatis C and Coinfection with HIV (CHC/HIV) Study 6:

215 **PEGASYS Monotherapy and PEGASYS/COPEGUS Combination**

216 Therapy

217 In Study 6, patients with CHC/HIV were randomized to receive either PEGASYS 180 µg sc once weekly (qw) plus an oral placebo, PEGASYS 180 µg qw plus COPEGUS 218 800 mg po daily or ROFERON-A (interferon alfa-2a), 3 MIU sc tiw plus COPEGUS 800 219 220 mg po daily. All patients received 48 weeks of therapy and sustained virologic response 221 (SVR) was assessed at 24 weeks of treatment-free follow-up. COPEGUS or placebo 222 treatment assignment was blinded in the PEGASYS treatment arms. All patients were 223 adults, had compensated liver disease, detectable hepatitis C virus, liver biopsy diagnosis 224 of chronic hepatitis C, and were previously untreated with interferon. Patients also had 225 CD4+ cell count \geq 200 cells/µL or CD4+ cell count \geq 100 cells/µL but <200 cells/µL and HIV-1 RNA <5000 copies/mL, and stable status of HIV. Approximately 15% of patients 226 227 in the study had cirrhosis. Results are shown in Table 4.

228Table 4Sustained Virologic Response in Patients With Chronic229Hepatitis C Coinfected with HIV (Study 6)

	ROFERON-A +	PEGASYS +	PEGASYS +	
	COPEGUS 800 mg	Placebo	COPEGUS 800 mg	
	(N=289)	(N=289)	(N=290)	
All patients	33 (11%)*	58 (20%)*	116 (40%)	
Genotype 1	12/171 (7%)	24/175 (14%)	51/176 (29%)	
Genotypes 2, 3	18/89 (20%)	32/90 (36%)	59/95 (62%)	

230 *PEGASYS + COPEGUS vs. PEGASYS; PEGASYS + COPEGUS vs. ROFERON-A + COPEGUS p 231 value <0.0001 (Cochran-Mantel-Haenszel).

232

Treatment response rates are lower in CHC/HIV patients with poor prognostic factors (including HCV genotype 1, HCV RNA >800,000 IU/mL, and cirrhosis) receiving pegylated interferon alpha therapy. Geographic region is not a prognostic factor for response. However, poor prognostic factors occur more frequently in the US population than in the non-US population.

Of the patients who did not demonstrate either undetectable HCV RNA or at least a
2log₁₀ reduction from baseline in HCV RNA titer by 12 weeks of PEGASYS and
COPEGUS combination therapy, 2% (2/85) achieved an SVR.

In CHC patients with HIV coinfection who received 48 weeks of PEGASYS alone or in
 combination with COPEGUS treatment, mean and median HIV RNA titers did not
 increase above baseline during treatment or 24 weeks post-treatment.

244 Chronic Hepatitis B Studies 7 and 8: PEGASYS Monotherapy

The safety and effectiveness of PEGASYS for the treatment of chronic hepatitis B were assessed in controlled clinical trials in HBeAg positive (Study 7) and HBeAg negative (Study 8) patients with chronic hepatitis B.

Patients were randomized to PEGASYS 180 µg sc once weekly (qw), PEGASYS 180 µg
sc qw combined with lamivudine 100 mg once daily po or lamivudine 100 mg once daily
po. All patients received 48 weeks of their assigned therapy followed by 24 weeks of
treatment-free follow-up. Assignment to receipt of PEGASYS or no PEGASYS was not
masked.

All patients were adults with compensated liver disease, had chronic hepatitis B virus (HBV) infection, and evidence of HBV replication (serum HBV >500,000 copies/mL for Study 7 and >100,000 copies/mL for Study 8) as measured by PCR (COBAS AMPLICOR[®] HBV Assay). All patients had serum alanine aminotransferase (ALT) between 1 and 10 times the upper limit of normal (ULN) and liver biopsy findings compatible with the diagnosis of chronic hepatitis.

The results observed in the PEGASYS and lamivudine monotherapy groups are shown inTable 5.

261Table 5Percentage of Patients with Serological, Virological,262Biochemical, and Histological Response

	Study 7 HBeAg positive			Study 8 HBeAg negative		
-	Lami	vudine	PEGASYS	Lami	vudine	PEGASYS
	N =	= 272	N = 271	N =	= 181	N = 177
	EOT ¹	EOF ²	EOF ²	EOT ¹	EOF ²	EOF ²
HBeAg Seroconversion (%)	20	19*	32*	NA	NA	NA
HBV DNA Response (%) ³	62	22***	32***	85	29**	43**
ALT Normalization (%)	62	28	41	73	44**	59**
HBsAg Seroconversion (%)	0	0	3	1	0	3
· ·	N =	= 184	N = 207	N = 125		N = 143
Histological Improvement (%) ⁴	ND	40	41	ND	41	48
Changes in Ishak fibrosis score compared to baseline (%):						
- Improved ⁵	ND	32	25	ND	31	32

- Unchanged	20	25	23	30
- Worsened ⁵	16	26	15	19

263 ¹End of Treatment (week 48)

 2 End of follow-up – 24 weeks post-treatment (week 72)

265 ³<100,000 copies/mL for HBeAg positive and <20,000 copies/mL for HBeAg negative patients

 $^{4} \ge 2$ point decrease in Ishak necro-inflammatory score from baseline with no worsening of the Ishak

267 fibrosis score. Not all patients provided both initial and end of follow-up biopsies (missing biopsy rates:

- 268 19%-24% in the PEGASYS and 31%-32% in the Lamivudine arms)
- ⁵Change of 1 point or more in Ishak fibrosis score

270 *p<0.001; **p<0.01; ***p=0.012 (primary efficacy endpoints Cochran-Mantel-Haenszel test comparisons
 271 of PEGASYS to Lamivudine)

272

PEGASYS co-administered with lamivudine did not result in any additional sustained
 response when compared to PEGASYS monotherapy.

Conclusions regarding comparative efficacy of PEGASYS and lamivudine treatment
based upon the end of follow-up results are limited by the different mechanisms of action
of the two compounds. Most treatment effects of lamivudine are unlikely to persist 24
weeks after therapy is withdrawn.

279 INDICATIONS AND USAGE

PEGASYS, peginterferon alfa-2a, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that is clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy).

287 PEGASYS is indicated for the treatment of adult patients with HBeAg positive and
288 HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of
289 viral replication and liver inflammation.

290 CONTRAINDICATIONS

291 PEGASYS is contraindicated in patients with:

- Hypersensitivity to PEGASYS or any of its components
- Autoimmune hepatitis
- Hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic patients before or during treatment

Hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic
 CHC patients coinfected with HIV before or during treatment

PEGASYS is contraindicated in neonates and infants because it contains benzyl alcohol.
Benzyl alcohol is associated with an increased incidence of neurologic and other
complications in neonates and infants, which are sometimes fatal.

- 301 PEGASYS and COPEGUS combination therapy is additionally contraindicated in:
- Patients with known hypersensitivity to COPEGUS or to any component of the tablet
- 303 Women who are pregnant
- Men whose female partners are pregnant
- Patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia)

306 WARNINGS

307 General

Patients should be monitored for the following serious conditions, some of which may
 become life threatening. Patients with persistently severe or worsening signs or
 symptoms should have their therapy withdrawn (see BOXED WARNING).

311 Neuropsychiatric

312 Life-threatening or fatal neuropsychiatric reactions may manifest in patients receiving 313 therapy with PEGASYS and include suicide, suicidal ideation, homicidal ideation, 314 depression, relapse of drug addiction, and drug overdose. These reactions may occur in 315 patients with and without previous psychiatric illness.

316 PEGASYS should be used with extreme caution in patients who report a history of 317 depression. Neuropsychiatric adverse events observed with alpha interferon treatment 318 include aggressive behavior, psychoses, hallucinations, bipolar disorders, and mania. 319 Physicians should monitor all patients for evidence of depression and other psychiatric 320 symptoms. Patients should be advised to report any sign or symptom of depression or 321 suicidal ideation to their prescribing physicians. In severe cases, therapy should be 322 stopped immediately and psychiatric intervention instituted (see ADVERSE 323 **REACTIONS and DOSAGE AND ADMINISTRATION).**

324 Infections

325 Serious and severe bacterial infections, some fatal, have been observed in patients treated 326 with alpha interferons including PEGASYS. Some of the infections have been associated 327 with neutropenia. PEGASYS should be discontinued in patients who develop severe 328 infections and appropriate antibiotic therapy instituted.

329 Bone Marrow Toxicity

PEGASYS suppresses bone marrow function and may result in severe cytopenias.
 Ribavirin may potentiate the neutropenia and lymphopenia induced by alpha interferons
 including PEGASYS. Very rarely alpha interferons may be associated with aplastic
 anemia. It is advised that complete blood counts (CBC) be obtained pre-treatment and
 monitored routinely during therapy (see PRECAUTIONS: Laboratory Tests).

PEGASYS and COPEGUS should be used with caution in patients with baseline neutrophil counts <1500 cells/mm³, with baseline platelet counts <90,000 cells/mm³ or baseline hemoglobin <10 g/dL. PEGASYS therapy should be discontinued, at least temporarily, in patients who develop severe decreases in neutrophil and/or platelet counts (see **DOSAGE AND ADMINISTRATION: Dose Modifications**).

340 Severe neutropenia and thrombocytopenia occur with a greater incidence in HIV 341 coinfected patients than monoinfected patients and may result in serious infections or 342 bleeding (see **ADVERSE REACTIONS**).

343 Cardiovascular Disorders

344 Hypertension, supraventricular arrhythmias, chest pain, and myocardial infarction have 345 been observed in patients treated with PEGASYS.

PEGASYS should be administered with caution to patients with pre-existing cardiac
disease. Because cardiac disease may be worsened by ribavirin-induced anemia, patients
with a history of significant or unstable cardiac disease should not use COPEGUS (see
WARNINGS: Anemia and COPEGUS Package Insert).

350 Hepatic Failure and Hepatitis Exacerbations

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic 351 decompensation and death when treated with alpha interferons, including PEGASYS. 352 Cirrhotic CHC patients coinfected with HIV receiving highly active antiretroviral therapy 353 (HAART) and interferon alfa-2a with or without ribavirin appear to be at increased risk 354 for the development of hepatic decompensation compared to patients not receiving 355 HAART. In Study 6, among 129 CHC/HIV cirrhotic patients receiving HAART, 14 356 (11%) of these patients across all treatment arms developed hepatic decompensation 357 358 resulting in 6 deaths. All 14 patients were on NRTIs, including stavudine, didanosine, abacavir, zidovudine, and lamivudine. These small numbers of patients do not permit 359 discrimination between specific NRTIs for the associated risk. During treatment, 360 361 patients' clinical status and hepatic function should be closely monitored, and PEGASYS treatment should be immediately discontinued if decompensation (Child-Pugh score ≥ 6) 362 is observed (see CONTRAINDICATIONS). 363

Exacerbations of hepatitis during hepatitis B therapy are not uncommon and are 364 365 characterized by transient and potentially severe increases in serum ALT. Chronic hepatitis B patients experienced transient acute exacerbations (flares) of hepatitis B (ALT 366 elevation >10-fold higher than the upper limit of normal) during PEGASYS treatment 367 (12% and18%) and post-treatment (7% and12%) in HBeAg negative and HBeAg positive 368 patients, respectively. Marked transaminase flares while on PEGASYS therapy have been 369 accompanied by other liver test abnormalities. Patients experiencing ALT flares should 370 receive more frequent monitoring of liver function. PEGASYS dose reduction should be 371 considered in patients experiencing transaminase flares. If ALT increases are progressive 372 despite reduction of PEGASYS dose or are accompanied by increased bilirubin or 373 374 evidence of hepatic decompensation, PEGASYS should be immediately discontinued ADVERSE and DOSAGE AND 375 **REACTIONS:** Hepatitis B (see 376 **ADMINISTRATION:** Dose Modifications).

377 Hypersensitivity

378 Severe acute hypersensitivity reactions (e.g., urticaria, angioedema, bronchoconstriction, 379 and anaphylaxis) have been rarely observed during alpha interferon and ribavirin therapy.

380 If such reaction occurs, therapy with PEGASYS and COPEGUS should be discontinued

381 and appropriate medical therapy immediately instituted.

382 Endocrine Disorders

PEGASYS causes or aggravates hypothyroidism and hyperthyroidism. Hyperglycemia, hypoglycemia, and diabetes mellitus have been observed to develop in patients treated with PEGASYS. Patients with these conditions at baseline who cannot be effectively treated by medication should not begin PEGASYS therapy. Patients who develop these conditions during treatment and cannot be controlled with medication may require discontinuation of PEGASYS therapy.

389 Autoimmune Disorders

390 Development or exacerbation of autoimmune disorders including myositis, hepatitis, 391 thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, 392 rheumatoid arthritis, interstitial nephritis, thyroiditis, and systemic lupus erythematosus 393 have been reported in patients receiving alpha interferon. PEGASYS should be used with 394 caution in patients with autoimmune disorders.

395 **Pulmonary Disorders**

396 Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial
397 pneumonitis and sarcoidosis, some resulting in respiratory failure and/or patient deaths,
398 may be induced or aggravated by PEGASYS or alpha interferon therapy. Patients who
399 develop persistent or unexplained pulmonary infiltrates or pulmonary function
400 impairment should discontinue treatment with PEGASYS.

401 Colitis

Ulcerative and hemorrhagic/ischemic colitis, sometimes fatal, have been observed within
12 weeks of starting alpha interferon treatment. Abdominal pain, bloody diarrhea, and
fever are the typical manifestations of colitis. PEGASYS should be discontinued
immediately if these symptoms develop. The colitis usually resolves within 1 to 3 weeks
of discontinuation of alpha interferon.

407 **Pancreatitis**

Pancreatitis, sometimes fatal, has occurred during alpha interferon and ribavirin
treatment. PEGASYS and COPEGUS should be suspended if symptoms or signs
suggestive of pancreatitis are observed. PEGASYS and COPEGUS should be
discontinued in patients diagnosed with pancreatitis.

412 **Ophthalmologic Disorders**

413 Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein 414 thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, and papilledema 415 are induced or aggravated by treatment with PEGASYS or other alpha interferons. All 416 patients should receive an eye examination at baseline. Patients with pre-existing 417 ophthalmologic disorders (e.g., diabetic or hypertensive retinopathy) should receive

418 periodic ophthalmologic exams during interferon alpha treatment. Any patient who
419 develops ocular symptoms should receive a prompt and complete eye examination.
420 PEGASYS treatment should be discontinued in patients who develop new or worsening
421 ophthalmologic disorders.

422 **Pregnancy: Use with Ribavirin (also, see COPEGUS Package Insert)**

Ribavirin may cause birth defects and/or death of the exposed fetus. Extreme care 423 must be taken to avoid pregnancy in female patients and in female partners of male 424 425 patients taking PEGASYS and COPEGUS combination therapy. COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A 426 NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY 427 PRIOR TO INITIATION OF THERAPY. Women of childbearing potential and 428 men must use two forms of effective contraception during treatment and for at least 429 6 months after treatment has concluded. Routine monthly pregnancy tests must be 430 performed during this time (see BOXED WARNING, CONTRAINDICATIONS, 431 **PRECAUTIONS: Information for Patients, and COPEGUS Package Insert).** 432

433 Anemia

The primary toxicity of ribavirin is hemolytic anemia. Hemoglobin <10 g/dL was 434 observed in approximately 13% of COPEGUS and PEGASYS treated patients in chronic 435 436 hepatitis C clinical trials (see PRECAUTIONS: Laboratory Tests). The anemia associated with COPEGUS occurs within 1 to 2 weeks of initiation of therapy with 437 maximum drop in hemoglobin observed during the first eight weeks. BECAUSE THE 438 INITIAL DROP IN HEMOGLOBIN MAY BE SIGNIFICANT, IT IS ADVISED THAT 439 440 HEMOGLOBIN OR HEMATOCRIT BE OBTAINED PRE-TREATMENT AND AT WEEK 2 AND WEEK 4 OF THERAPY OR MORE FREQUENTLY IF CLINICALLY 441 INDICATED. Patients should then be followed as clinically appropriate. 442

Fatal and nonfatal myocardial infarctions have been reported in patients with anemia 443 caused by ribavirin. Patients should be assessed for underlying cardiac disease before 444 initiation of ribavirin therapy. Patients with pre-existing cardiac disease should have 445 electrocardiograms administered before treatment, and should be appropriately monitored 446 during therapy. If there is any deterioration of cardiovascular status, therapy should be 447 suspended or discontinued (see DOSAGE AND ADMINISTRATION: COPEGUS 448 Dosage Modification Guidelines). Because cardiac disease may be worsened by drug-449 induced anemia, patients with a history of significant or unstable cardiac disease should 450 not use COPEGUS (see COPEGUS Package Insert). 451

452 **Renal**

453 It is recommended that renal function be evaluated in all patients started on COPEGUS.

454 COPEGUS should not be administered to patients with creatinine clearance <50 mL/min

455 (see CLINICAL PHARMACOLOGY: Special Populations).

456 **PRECAUTIONS**

457 General

The safety and efficacy of PEGASYS alone or in combination with COPEGUS have not been established in:

- Patients who have failed alpha interferon treatment with or without ribavirin
- Liver or other organ transplant recipients
- Hepatitis B patients coinfected with HCV or HIV
- Hepatitis C patients coinfected with HBV or coinfected with HIV with a CD4+ cell
 count <100 cells/μL.

465

466 Caution should be exercised in initiating treatment in any patient with baseline risk of 467 severe anemia (e.g., spherocytosis, history of GI bleeding).

468 **Renal Impairment**

A 25% to 45% higher exposure to PEGASYS is seen in subjects undergoing
hemodialysis. In patients with impaired renal function, signs and symptoms of interferon
toxicity should be closely monitored. Doses of PEGASYS should be adjusted
accordingly. PEGASYS should be used with caution in patients with creatinine clearance
<50 mL/min (see DOSAGE AND ADMINISTRATION: Dose Modifications).

474 COPEGUS should not be used in patients with creatinine clearance <50 mL/min (see
 475 COPEGUS Package Insert).

476 **Information for Patients**

Patients receiving PEGASYS alone or in combination with COPEGUS should be
directed in its appropriate use, informed of the benefits and risks associated with
treatment, and referred to the PEGASYS and, if applicable, COPEGUS (ribavirin)
MEDICATION GUIDES.

481 PEGASYS and COPEGUS combination therapy must not be used by women who are 482 pregnant or by men whose female partners are pregnant. COPEGUS therapy should not 483 be initiated until a report of a negative pregnancy test has been obtained immediately before starting therapy. Female patients of childbearing potential and male patients with 484 485 female partners of childbearing potential must be advised of the teratogenic/embryocidal 486 risks and must be instructed to practice effective contraception during COPEGUS therapy and for 6 months post-therapy. Patients should be advised to notify the healthcare 487 488 provider immediately in the event of a pregnancy (see CONTRAINDICATIONS and 489 WARNINGS).

Women of childbearing potential and men must use two forms of effective contraception 490 during treatment and during the 6 months after treatment has been stopped; routine 491 492 pregnancy tests must be performed during this time (see monthly 493 **CONTRAINDICATIONS** and **COPEGUS** Package Insert).

To monitor maternal and fetal outcomes of pregnant women exposed to COPEGUS, the Ribavirin Pregnancy Registry has been established. Patients should be encouraged to register by calling 1-800-593-2214.

497 Patients should be advised that laboratory evaluations are required before starting therapy
498 and periodically thereafter (see Laboratory Tests). Patients should be instructed to
499 remain well hydrated, especially during the initial stages of treatment. Patients should be
500 advised to take COPEGUS with food.

501 Patients should be informed that it is not known if therapy with PEGASYS alone or in 502 combination with COPEGUS will prevent transmission of HCV or HBV infection to 503 others or prevent cirrhosis, liver failure or liver cancer that might result from HCV or 504 HBV infection. Patients who develop dizziness, confusion, somnolence, and fatigue 505 should be cautioned to avoid driving or operating machinery.

506 If home use is prescribed, a puncture-resistant container for the disposal of used needles 507 and syringes should be supplied to the patients. Patients should be thoroughly instructed 508 in the importance of proper disposal and cautioned against any reuse of any needles and 509 syringes. The full container should be disposed of according to the directions provided by 510 the physician (see **MEDICATION GUIDE**).

511 Laboratory Tests

512 Before beginning PEGASYS or PEGASYS and COPEGUS combination therapy, 513 standard hematological and biochemical laboratory tests are recommended for all 514 patients. Pregnancy screening for women of childbearing potential must be performed.

515 After initiation of therapy, hematological tests should be performed at 2 weeks and 4 516 weeks and biochemical tests should be performed at 4 weeks. Additional testing should 517 be performed periodically during therapy. In the clinical studies, the CBC (including 518 hemoglobin level and white blood cell and platelet counts) and chemistries (including 519 liver function tests and uric acid) were measured at 1, 2, 4, 6, and 8 weeks, and then 520 every 4 to 6 weeks or more frequently if abnormalities were found. Thyroid stimulating 521 hormone (TSH) was measured every 12 weeks. Monthly pregnancy testing should be 522 performed during combination therapy and for 6 months after discontinuing therapy.

523 The entrance criteria used for the clinical studies of PEGASYS may be considered as a 524 guideline to acceptable baseline values for initiation of treatment:

- Platelet count \geq 90,000 cells/mm³ (as low as 75,000 cells/mm³ in HCV patients with cirrhosis or 70,000 cells/mm³ in patients with CHC and HIV)
- 527 Absolute neutrophil count (ANC) ≥ 1500 cells/mm³
- Serum creatinine concentration <1.5 x upper limit of normal
- TSH and T_4 within normal limits or adequately controlled thyroid function
- CD4+ cell count ≥200 cells/µL or CD4+ cell count ≥100 cells/µL but <200 cells/µL
 and HIV-1 RNA <5000 copies/mL in patients coinfected with HIV

- Hemoglobin ≥12 g/dL for women and ≥13 g/dL for men in CHC monoinfected
 patients
- Hemoglobin ≥ 11 g/dL for women and ≥ 12 g/dL for men in patients with CHC and HIV.

536 PEGASYS treatment was associated with decreases in WBC, ANC, lymphocytes, and
537 platelet counts often starting within the first 2 weeks of treatment (see ADVERSE
538 REACTIONS). Dose reduction is recommended in patients with hematologic
539 abnormalities (see DOSAGE AND ADMINISTRATION: Dose Modifications).

540 While fever is commonly caused by PEGASYS therapy, other causes of persistent fever
541 must be ruled out, particularly in patients with neutropenia (see WARNINGS:
542 Infections).

543 In chronic hepatitis C, transient elevations in ALT (2-fold to 5-fold above baseline) were 544 observed in some patients receiving PEGASYS, and were not associated with 545 deterioration of other liver function tests. When the increase in ALT levels is progressive 546 despite dose reduction or is accompanied by increased bilirubin, PEGASYS therapy 547 should be discontinued (see DOSAGE AND **ADMINISTRATION:** Dose 548 **Modifications**).

549 Unlike hepatitis C, during hepatitis B therapy and follow up, transient elevations in ALT
550 of 5 to 10 x ULN were observed in 25% and 27% and of >10 x ULN were observed in
551 12% and 18%, of HBeAg negative and HBeAg positive patients, respectively. These
552 ALT elevations have been accompanied by other liver test abnormalities (see
553 WARNINGS: Hepatic Failure and Hepatitis Exacerbations and DOSAGE AND
554 ADMINISTRATION: Dose Modifications).

555 **Drug Interactions**

556 Theophylline

557 Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated 558 with an inhibition of P450 1A2 and a 25% increase in theophylline AUC. Theophylline 559 serum levels should be monitored and appropriate dose adjustments considered for 560 patients given both theophylline and PEGASYS (see CLINICAL PHARMACOLOGY: 561 **Drug Interactions**).

562 Methadone

In a PK study of HCV patients concomitantly receiving methadone, treatment with
PEGASYS once weekly for 4 weeks was associated with methadone levels that were
10% to 15% higher than at baseline (see CLINICAL PHARMACOLOGY: Drug
Interactions). The clinical significance of this finding is unknown; however, patients
should be monitored for the signs and symptoms of methadone toxicity.

568 Nucleoside Analogues

569 NRTIs

570 In Study 6 among the CHC/HIV coinfected cirrhotic patients receiving NRTIs cases of

571 hepatic decompensation (some fatal) were observed (see WARNINGS: Hepatic Failure

572 and Hepatitis Exacerbations).

573 Patients receiving PEGASYS/COPEGUS and NRTIs should be closely monitored for 574 treatment associated toxicities. Physicians should refer to prescribing information for the 575 respective NRTIs for guidance regarding toxicity management. In addition, dose 576 reduction or discontinuation of PEGASYS, COPEGUS or both should also be considered 577 if worsening toxicities are observed (see WARNINGS, PRECAUTIONS, DOSAGE 578 AND ADMINISTRATION: Dose Modifications).

579 Didanosine

580 Co-administration of COPEGUS and didanosine is not recommended. Reports of fatal 581 hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic 582 hyperlactatemia/lactic acidosis have been reported in clinical trials (see CLINICAL 583 **PHARMACOLOGY:** Drug Interactions).

584 Zidovudine

585 In Study 6, patients who were administered zidovudine in combination with 586 PEGASYS/COPEGUS developed severe neutropenia (ANC <500) and severe anemia 587 (hemoglobin $\leq 8 \text{ g/dL}$) more frequently than similar patients not receiving zidovudine 588 (neutropenia 15% vs. 9%) (anemia 5% vs. 1%).

589 Lamivudine, Stavudine, and Zidovudine

590 In vitro studies have shown ribavirin can reduce the phosphorylation of pyrimidine 591 nucleoside analogs such as lamivudine, stavudine, and zidovudine. No evidence of a 592 pharmacokinetic or pharmacodynamic interaction was seen when ribavirin was co-593 administered with lamivudine, stavudine, and/or zidovudine in HIV/HCV coinfected 594 patients (see CLINICAL PHARMACOLOGY: Drug Interactions).

595 Carcinogenesis, Mutagenesis, Impairment of Fertility

596 Carcinogenesis

597 PEGASYS has not been tested for its carcinogenic potential.

598 **Mutagenesis**

599 PEGASYS did not cause DNA damage when tested in the Ames bacterial mutagenicity 600 assay and in the in vitro chromosomal aberration assay in human lymphocytes, either in 601 the presence or absence of metabolic activation.

Use with Ribavirin 602

Ribavirin is genotoxic and mutagenic. The carcinogenic potential of ribavirin has not 603 604 been fully determined. In a p53 (+/-) mouse carcinogenicity study at doses up to the 605 maximum tolerated dose of 100 mg/kg/day ribavirin was not oncogenic. However, on a 606 body surface area basis, this dose was 0.5 times maximum recommended human 24-hour

dose of ribavirin. A study in rats to assess the carcinogenic potential of ribavirin is
 ongoing (see COPEGUS Package Insert).

609 Impairment of Fertility

610 PEGASYS may impair fertility in women. Prolonged menstrual cycles and/or 611 amenorrhea were observed in female cynomolgus monkeys given sc injections of $600 \,\mu g/kg/dose$ (7200 $\mu g/m^2/dose$) of PEGASYS every other day for one month, at 612 613 approximately 180 times the recommended weekly human dose for a 60 kg person (based 614 on body surface area). Menstrual cycle irregularities were accompanied by both a 615 decrease and delay in the peak 17^β-estradiol and progesterone levels following 616 administration of PEGASYS to female monkeys. A return to normal menstrual rhythm 617 followed cessation of treatment. Every other day dosing with 100 μ g/kg (1200 μ g/m²) 618 PEGASYS (equivalent to approximately 30 times the recommended human dose) had no 619 effects on cycle duration or reproductive hormone status.

620 The effects of PEGASYS on male fertility have not been studied. However, no adverse 621 effects on fertility were observed in male Rhesus monkeys treated with non-pegylated 622 interferon alfa-2a for 5 months at doses up to 25×10^6 IU/kg/day.

623 Use with Ribavirin

624 Ribavirin has shown reversible toxicity in animal studies of male fertility (see 625 **COPEGUS Package Insert**).

626 **Pregnancy**

627 Pregnancy: Category C

628 PEGASYS has not been studied for its teratogenic effect. Non-pegylated interferon alfa-629 2a treatment of pregnant Rhesus monkeys at approximately 20 to 500 times the human 630 weekly dose resulted in a statistically significant increase in abortions. No teratogenic 631 effects were seen in the offspring delivered at term. PEGASYS should be assumed to 632 have abortifacient potential. There are no adequate and well-controlled studies of 633 PEGASYS in pregnant women. PEGASYS is to be used during pregnancy only if the 634 potential benefit justifies the potential risk to the fetus. PEGASYS is recommended for 635 use in women of childbearing potential only when they are using effective contraception 636 during therapy.

637 **Pregnancy: Category X: Use With Ribavirin (see CONTRAINDICATIONS)**

638 Significant teratogenic and/or embryocidal effects have been demonstrated in all
639 animal species exposed to ribavirin. COPEGUS therapy is contraindicated in
640 women who are pregnant and in the male partners of women who are pregnant (see
641 CONTRAINDICATIONS, WARNINGS, and COPEGUS Package Insert).

642 *Ribavirin Pregnancy Registry*

A Ribavirin Pregnancy Registry has been established to monitor maternal and fetal
outcomes of pregnancies of female patients and female partners of male patients exposed
to ribavirin during treatment and for 6 months following cessation of treatment.
Healthcare providers and patients are encouraged to report such cases by calling 1-800593-2214.

648 Nursing Mothers

649 It is not known whether peginterferon or ribavirin or its components are excreted in 650 human milk. The effect of orally ingested peginterferon or ribavirin from breast milk on 651 the nursing infant has not been evaluated. Because of the potential for adverse reactions 652 from the drugs in nursing infants, a decision must be made whether to discontinue 653 nursing or discontinue PEGASYS and COPEGUS treatment.

654 **Pediatric Use**

The safety and effectiveness of PEGASYS, alone or in combination with COPEGUS in patients below the age of 18 years have not been established.

657 PEGASYS contains benzyl alcohol. Benzyl alcohol has been reported to be associated 658 with an increased incidence of neurological and other complications in neonates and 659 infants, which are sometimes fatal (see **CONTRAINDICATIONS**).

660 Geriatric Use

Younger patients have higher virologic response rates than older patients. Clinical studies 661 662 of PEGASYS alone or in combination with COPEGUS did not include sufficient 663 numbers of subjects aged 65 or over to determine whether they respond differently from 664 vounger subjects. Adverse reactions related to alpha interferons, such as CNS, cardiac, and systemic (e.g., flu-like) effects may be more severe in the elderly and caution should 665 be exercised in the use of PEGASYS in this population. PEGASYS and COPEGUS are 666 667 excreted by the kidney, and the risk of toxic reactions to this therapy may be greater in 668 patients with impaired renal function. Because elderly patients are more likely to have 669 decreased renal function, care should be taken in dose selection and it may be useful to 670 monitor renal function. PEGASYS should be used with caution in patients with creatinine 671 clearance <50 mL/min and COPEGUS should not be administered to patients with creatinine clearance <50 mL/min. 672

673 **ADVERSE REACTIONS**

674 PEGASYS alone or in combination with COPEGUS causes a broad variety of serious 675 adverse reactions (see **BOXED WARNING** and **WARNINGS**). The most common life-676 threatening or fatal events induced or aggravated by PEGASYS and COPEGUS were 677 depression, suicide, relapse of drug abuse/overdose, and bacterial infections, each 678 occurring at a frequency of <1%. Hepatic decompensation occurred in 2% (10/574) of 679 CHC/HIV patients (see **WARNINGS: Hepatic Failure and Hepatitis Exacerbations**).

680 In all hepatitis C studies, one or more serious adverse reactions occurred in 10% of CHC monoinfected patients and in 19% of CHC/HIV patients receiving PEGASYS alone or in **68**1 combination with COPEGUS. The most common serious adverse event (3% in CHC and 682 683 5% in CHC/HIV) was bacterial infection (e.g., sepsis, osteomyelitis, endocarditis, 684 pyelonephritis, pneumonia). Other SAEs occurred at a frequency of <1% and included: 685 suicide, suicidal ideation, psychosis, aggression, anxiety, drug abuse and drug overdose, 686 angina, hepatic dysfunction, fatty liver, cholangitis, arrhythmia, diabetes mellitus, 687 autoimmune phenomena (e.g., hyperthyroidism, hypothyroidism, sarcoidosis, systemic 688 lupus erythematosus, rheumatoid arthritis), peripheral neuropathy, aplastic anemia, peptic

ulcer, gastrointestinal bleeding, pancreatitis, colitis, corneal ulcer, pulmonary embolism,
 coma, myositis, cerebral hemorrhage, and thrombotic thrombocytopenic purpura.

691 Nearly all patients in clinical trials experienced one or more adverse events. For hepatitis 692 C patients, the most commonly reported adverse reactions were psychiatric reactions, 693 including depression, insomnia, irritability, anxiety, and flu-like symptoms such as 694 fatigue, pyrexia, myalgia, headache, and rigors. Other common reactions were anorexia, 695 nausea and vomiting, diarrhea, arthralgias, injection site reactions, alopecia, and pruritus.

696 Overall 11% of CHC monoinfected patients receiving 48 weeks of therapy with 697 PEGASYS either alone or in combination with COPEGUS discontinued therapy; 16% of 698 CHC/HIV coinfected patients discontinued therapy. The most common reasons for 699 discontinuation of therapy were psychiatric, flu-like syndrome (e.g., lethargy, fatigue, 690 headache), dermatologic, and gastrointestinal disorders and laboratory abnormalities 691 (thrombocytopenia, neutropenia, and anemia).

Overall 39% of patients with CHC or CHC/HIV required modification of PEGASYS
and/or COPEGUS therapy. The most common reason for dose modification of
PEGASYS in CHC and CHC/HIV patients was for laboratory abnormalities, neutropenia
(20% and 27%, respectively) and thrombocytopenia (4% and 6%, respectively). The most
common reason for dose modification of COPEGUS in CHC and CHC/HIV patients was
anemia (22% and 16%, respectively).

PEGASYS dose was reduced in 12% of patients receiving 1000 mg to 1200 mg
COPEGUS for 48 weeks and in 7% of patients receiving 800 mg COPEGUS for 24
weeks. COPEGUS dose was reduced in 21% of patients receiving 1000 mg to 1200 mg
COPEGUS for 48 weeks and in 12% of patients receiving 800 mg COPEGUS for 24
weeks.

Chronic hepatitis C monoinfected patients treated for 24 weeks with PEGASYS and 800 mg COPEGUS were observed to have lower incidence of serious adverse events (3% vs. 10%), Hgb <10 g/dL (3% vs. 15%), dose modification of PEGASYS (30% vs. 36%) and COPEGUS (19% vs. 38%) and of withdrawal from treatment (5% vs. 15%) compared to patients treated for 48 weeks with PEGASYS and 1000 mg or 1200 mg COPEGUS. On the other hand the overall incidence of adverse events appeared to be similar in the two treatment groups.</p>

720 Because clinical trials are conducted under widely varying and controlled 721 conditions, adverse reaction rates observed in clinical trials of a drug cannot be 722 directly compared to rates in the clinical trials of another drug. Also, the adverse 723 event rates listed here may not predict the rates observed in a broader patient 724 population in clinical practice.

725Table 6Adverse Reactions Occurring in ≥5% of Patients in Chronic726Hepatitis C Clinical Trials (Pooled Studies 1, 2, 3, and727Study 4)

CHC Monotherapy (Pooled	CHC Combination Therapy
Studies 1-3)	Study 4

Body System	PEGASYS 180 μg 48 week†	ROFERON-A*†	PEGASYS 180 μg + 1000 mg or 1200 mg COPEGUS 48 week**	Intron [®] A + 1000 mg or 1200 mg REBETOL [®] 48 week**
	N=559	N=554	N=451	N=443
	%	%	%	%
Application Site Disorders				
Injection site reaction	22	18	23	16
Endocrine Disorders				
Hypothyroidism	3	2	4	5
Flu-like Symptoms and				· · · · · · · · · · · · · · · · · · ·
Signs				
Fatigue/Asthenia	56	57	65	68
Pyrexia	37	41	41	55
Rigors	35	44	25	37
Pain	11	12	10	9
Gastrointestinal	<u> </u>			
Nausea/Vomiting	24	33	25	29
Diarrhea	16	16	11	10
Abdominal pain	15	15	8	9
Dry mouth	6	3	4	7
Dyspepsia	<1	1	6	5
Hematologic‡				
Lymphopenia	3	5	14	12
Anemia	2	1	11	11
Neutropenia	21	8	27	8
Thrombocytopenia	5	2	5	<1
Metabolic and Nutritional				
Anorexia	17	17	24	26
Weight decrease	4	3	10	10
Musculoskeletal, Connective Tissue and Bone				
Myalgia	37	38	40	. 49
Arthralgia	28	29	22	23
Back pain	9	10	5	5

21

		therapy (Pooled dies 1-3)	CHC Combination Therapy Study 4		
Body System	PEGASYS 180 μg 48 week†	ROFERON-A*†	PEGASYS 180 μg + 1000 mg or 1200 mg COPEGUS 48 week**	Intron [®] A + 1000 mg or 1200 mg REBETOL [®] 48 week**	
	N=559	N=554	N=451	N=443	
	%	%	%	%	
Neurological					
Headache	54	58	43	49	
Dizziness (excluding vertigo)	16	12	14	14	
Memory impairment	5	4	6	5	
Resistance Mechanism Disorders					
Overall	10	6	12	10	
Psychiatric					
Irritability/Anxiety/	19	22	33	38	
Nervousness					
Insomnia	19	23	30	37	
Depression	18	19	20	28	
Concentration impairment	8	10	10	13	
Mood alteration	3	2	5	6	
Respiratory, Thoracic and Mediastinal					
Dyspnea	4	2	13	. 14	
Cough	4	3	10	7	
Dyspnea exertional	<1	<1	4	7	
Skin and Subcutaneous Tissue					
Alopecia	23	30	28	33	
Pruritus	12	8	19	18	
Dermatitis	8	3	16	13	
Dry skin	4	3	10	13	
Rash	5	4	8	5	
Sweating increased	6	7	6	5	
Eczema	1	1	5	4	

.

		therapy (Pooled dies 1-3)	CHC Combination Therapy Study 4	
Body System	РЕGASYS 180 µg 48 week†	ROFERON-A*†	PEGASYS 180 μg + 1000 mg or 1200 mg COPEGUS 48 week**	Intron [®] A + 1000 mg or 1200 mg REBETOL [®] 48 week**
	N=559	N=554	N=451	N=443
	%	%	%	%
Visual Disorders				
Vision blurred	4	2	5	2

728 † Pooled studies 1, 2, and 3

729 * Either 3 MIU or 6/3 MIU of ROFERON-A

730 **Study 4

731 \ddagger Severe hematologic abnormalities (lymphocyte <0.5 x 10⁹/L; hemoglobin <10 g/dL;

732 neutrophil $<0.75 \times 10^{9}$ /L; platelet $<50 \times 10^{9}$ /L).

733

734 CHC With HIV Coinfection

The adverse event profile of coinfected patients treated with PEGASYS and COPEGUS in Study 6 was generally similar to that shown for monoinfected patients in Study 4 (Table 6). Events occurring more frequently in coinfected patients were neutropenia (40%), anemia (14%), thrombocytopenia (8%), weight decrease (16%), and mood alteration (9%).

740 Chronic Hepatitis B

In clinical trials of 48 week treatment duration, the adverse event profile of PEGASYS in
chronic hepatitis B was similar to that seen in chronic hepatitis C PEGASYS
monotherapy use, except for exacerbations of hepatitis (see WARNINGS: Hepatic
Failure and Hepatitis Exacerbations). Six percent of PEGASYS treated patients in the
hepatitis B studies experienced one or more serious adverse events.

The most common or important serious adverse events in the hepatitis B studies were
infections (sepsis, appendicitis, tuberculosis, influenza), hepatitis B flares, anaphylactic
shock, thrombotic thrombocytopenic purpura.

The most commonly observed adverse reactions were pyrexia (54% vs. 4%), headache (27% vs. 9%), fatigue (24% vs. 10%), myalgia (26% vs. 4%), alopecia (18% vs. 2%), and anorexia (16% vs. 3%) in the PEGASYS and lamivudine groups respectively.

Overall 5% of hepatitis B patients discontinued PEGASYS therapy and 40% of patients
required modification of PEGASYS dose. The most common reason for dose
modification in patients receiving PEGASYS therapy was for laboratory abnormalities
including neutropenia (20%) thrombocytopenia (13%), and ALT disorders (11%).

756 Laboratory Test Values

The laboratory test values observed in the hepatitis B trials (except where noted below)
were similar to those seen in the PEGASYS monotherapy hepatitis C trials.

759 Neutrophils

760 In the hepatitis C studies, decreases in neutrophil count below normal were observed in 95% of all patients treated with PEGASYS either alone or in combination with 761 762 COPEGUS. Severe potentially life-threatening neutropenia (ANC $<0.5 \times 10^9$ /L) occurred 763 in 5% of CHC patients and 12% of CHC/HIV patients receiving PEGASYS either alone 764 or in combination with COPEGUS. Modification of PEGASYS dose for neutropenia 765 occurred in 17% of patients receiving PEGASYS monotherapy and 22% of patients 766 receiving PEGASYS/COPEGUS combination therapy. In the CHC/HIV patients 27% 767 required modification of interferon dosage for neutropenia. Two percent of patients with 768 CHC and 10% of patients with CHC/HIV required permanent reductions of PEGASYS 769 dosage and <1% required permanent discontinuation. Median neutrophil counts return to 770 pre-treatment levels 4 weeks after cessation of therapy (see DOSAGE AND 771 **ADMINISTRATION:** Dose Modifications).

772 Lymphocytes

773 Decreases in lymphocyte count are induced by interferon alpha therapy. PEGASYS plus 774 COPEGUS combination therapy induced decreases in median total lymphocyte counts 775 (56% in CHC and 40% in CHC/HIV, with median decrease of 1170 cells/mm³ in CHC and 800 cells/mm³ in CHC/HIV). In the hepatitis C studies, lymphopenia was observed 776 during both monotherapy (81%) and combination therapy with PEGASYS and 777 COPEGUS (91%). Severe lymphopenia (<0.5 x 10⁹/L) occurred in approximately 5% of 778 779 all monotherapy patients and 14% of all combination PEGASYS and COPEGUS therapy 780 recipients. Dose adjustments were not required by protocol. The clinical significance of 781 the lymphopenia is not known.

In CHC with HIV coinfection, CD4 counts decreased by 29% from baseline (median decrease of 137 cells/mm³) and CD8 counts decreased by 44% from baseline (median decrease of 389 cells/mm³) in the PEGASYS plus COPEGUS combination therapy arm.
Median lymphocyte CD4 and CD8 counts return to pre-treatment levels after 4 to 12 weeks of the cessation of therapy. CD4% did not decrease during treatment.

787 Platelets

In the hepatitis C studies, platelet counts decreased in 52% of CHC patients and 51% of CHC/HIV patients treated with PEGASYS alone (respectively median decrease of 41% and 35% from baseline), and in 33% of CHC patients and 47% of CHC/HIV patients receiving combination therapy with COPEGUS (median decrease of 30% from baseline). Moderate to severe thrombocytopenia (<50,000/mm³) was observed in 4% of CHC and 8% of CHC/HIV patients. Median platelet counts return to pre-treatment levels 4 weeks after the cessation of therapy.

795 Hemoglobin

796 In the hepatitis C studies, the hemoglobin concentration decreased below 12 g/dL in 17% 797 (median Hgb reduction of 2.2 g/dL) of monotherapy and 52% (median Hgb reduction of 798 3.7 g/dL) of combination therapy patients. Severe anemia (Hgb <10 g/dL) was 799 encountered in 13% of all patients receiving combination therapy and in 2% of CHC 800 patients and 8% of CHC/HIV patients receiving PEGASYS monotherapy. Dose 801 modification for anemia in COPEGUS recipients treated for 48 weeks occurred in 22% of 802 16% of CHC/HIV patients (see CHC patients and DOSAGE AND 803 **ADMINISTRATION:** Dose Modifications).

804 Triglycerides

Triglyceride levels are elevated in patients receiving alfa interferon therapy and were elevated in the majority of patients participating in clinical studies receiving either PEGASYS alone or in combination with COPEGUS. Random levels \geq 400 mg/dL were observed in about 20% of CHC patients. Severe elevations of triglycerides (>1000 mg/dL) occurred in 2% of CHC monoinfected patients.

- 810 In HCV/HIV coinfected patients, fasting levels \geq 400 mg/dL were observed in up to 36%
- 811 of patients receiving either PEGASYS alone or in combination with COPEGUS. Severe
- 812 elevations of triglycerides (>1000 mg/dL) occurred in 7% of coinfected patients.

813 ALT Elevations

814 Chronic Hepatitis C

815 One percent of patients in the hepatitis C trials experienced marked elevations (5- to 10-816 fold above the upper limit of normal) in ALT levels during treatment and follow-up. 817 These transaminase elevations were on occasion associated with hyperbilirubinemia and 818 were managed by dose reduction or discontinuation of study treatment. Liver function 819 test abnormalities were generally transient. One case was attributed to autoimmune 820 hepatitis, which persisted beyond study medication discontinuation (see **DOSAGE AND** 821 **ADMINISTRATION: Dose Modifications**).

822 Chronic Hepatitis B

823 Transient ALT elevations are common during hepatitis B therapy with PEGASYS. 824 Twenty-five percent and 27% of patients experienced elevations of 5 to 10 x ULN and 825 12% and 18% had elevations of >10 x ULN during treatment of HBeAg negative and 826 HBeAg positive disease, respectively. Flares have been accompanied by elevations of 827 total bilirubin and alkaline phosphatase and less commonly with prolongation of PT and 828 reduced albumin levels. Eleven percent of patients had dose modifications due to ALT 829 flares and <1% of patients were withdrawn from treatment (see WARNINGS: Hepatic 830 Failure and Hepatitis Exacerbations and DOSAGE AND ADMINISTRATION: 831 **Dose Modifications**).

ALT flares of 5 to 10 x ULN occurred in 13% and 16% of patients, while ALT flares of >10 x ULN occurred in 7% and 12% of patients in HBeAg negative and HBeAg positive disease, respectively, after discontinuation of PEGASYS therapy.

835 Thyroid Function

836 PEGASYS alone or in combination with COPEGUS was associated with the 837 development of abnormalities in thyroid laboratory values, some with associated clinical 838 manifestations. In the hepatitis C studies, hypothyroidism or hyperthyroidism requiring 839 treatment, dose modification or discontinuation occurred in 4% and 1% of PEGASYS 840 treated patients and 4% and 2% of PEGASYS and COPEGUS treated patients, 841 respectively. Approximately half of the patients, who developed thyroid abnormalities 842 during PEGASYS treatment, still had abnormalities during the follow-up period (see 843 **PRECAUTIONS:** Laboratory Tests).

844 Immunogenicity

845 Chronic Hepatitis C

Nine percent (71/834) of patients treated with PEGASYS with or without COPEGUS
developed binding antibodies to interferon alfa-2a, as assessed by an ELISA assay. Three
percent of patients (25/835) receiving PEGASYS with or without COPEGUS, developed
low-titer neutralizing antibodies (using an assay with a sensitivity of 100 INU/mL).

850 Chronic Hepatitis B

Twenty-nine percent (42/143) of hepatitis B patients treated with PEGASYS for 24
weeks developed binding antibodies to interferon alfa-2a, as assessed by an ELISA assay.
Thirteen percent of patients (19/143) receiving PEGASYS developed low-titer
neutralizing antibodies (using an assay with a sensitivity of 100 INU/mL).

The clinical and pathological significance of the appearance of serum neutralizing antibodies is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The percentage of patients whose test results were considered positive for antibodies is highly dependent on the sensitivity and specificity of the assays.

Additionally, the observed incidence of antibody positivity in these assays may be influenced by several factors including sample timing and handling, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to PEGASYS with the incidence of antibodies to other products may be misleading.

865 Postmarketing Experience

The following adverse reactions have been identified and reported during post-approval use of PEGASYS therapy: hearing impairment, hearing loss. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting or (3) strength of causal connection to PEGASYS.

873 **OVERDOSAGE**

There is limited experience with overdosage. The maximum dose received by any patient was 7 times the intended dose of PEGASYS (180 µg/day for 7 days). There were no serious reactions attributed to overdosages. Weekly doses of up to 630 µg have been administered to patients with cancer. Dose-limiting toxicities were fatigue, elevated liver enzymes, neutropenia, and thrombocytopenia. There is no specific antidote for PEGASYS. Hemodialysis and peritoneal dialysis are not effective.

880 **DOSAGE AND ADMINISTRATION**

There are no safety and efficacy data on treatment of chronic hepatitis C or hepatitis B for longer than 48 weeks. For patients with hepatitis C, consideration should be given to discontinuing therapy after 12 to 24 weeks of therapy if the patient has failed to demonstrate an early virologic response defined as undetectable HCV RNA or at least a 2log₁₀ reduction from baseline in HCV RNA titer by 12 weeks of therapy (see **CLINICAL STUDIES**).

A patient should self-inject PEGASYS only if the physician determines that it is
appropriate and the patient agrees to medical follow-up as necessary and training in
proper injection technique has been provided to him/her (see illustrated PEGASYS
MEDICATION GUIDE for directions on injection site preparation and injection
instructions).

PEGASYS should be inspected visually for particulate matter and discoloration before
administration, and not used if particulate matter is visible or product is discolored. Vials
and prefilled syringes with particulate matter or discoloration should be returned to the
pharmacist.

896 Chronic Hepatitis C

897 **PEGASYS Monotherapy**

898 The recommended dose of PEGASYS monotherapy for chronic hepatitis C is $180 \ \mu g$ (1.0 899 mL vial or 0.5 mL prefilled syringe) once weekly for 48 weeks by subcutaneous 900 administration in the abdomen or thigh.

901 **PEGASYS and COPEGUS Combination Therapy**

902 The recommended dose of PEGASYS when used in combination with ribavirin for 903 chronic hepatitis C is 180 μ g (1.0 mL vial or 0.5 mL prefilled syringe) once weekly. The 904 recommended dose of COPEGUS and duration for PEGASYS/COPEGUS therapy is 905 based on viral genotype (see Table 7).

906 The daily dose of COPEGUS is 800 mg to 1200 mg administered orally in two divided 907 doses. The dose should be individualized to the patient depending on baseline disease 908 characteristics (e.g., genotype), response to therapy, and tolerability of the regimen.

Since COPEGUS absorption increases when administered with a meal, patients areadvised to take COPEGUS with food.

911 Table 7 PEGASYS and COPEGUS Dosing Recommendations

Genotype	PEGASYS Dose	COPEGUS Dose	Duration
Construes 1 4	190	<75 kg = 1000 mg	48 weeks
Genotypes 1, 4	180 µg	≥75 kg = 1200 mg	48 weeks
Genotypes 2, 3	180 μg	800 mg	24 weeks

912 Genotypes 2 and 3 showed no increased response to treatment beyond 24 weeks (see Table 3).

913 Data on genotypes 5 and 6 are insufficient for dosing recommendations.

914

915 CHC with HIV Coinfection

916 **PEGASYS Monotherapy**

917 The recommended dose of PEGASYS monotherapy for chronic hepatitis C in patients

918 coinfected with HIV is 180 ug (1.0 mL vial or 0.5 mL prefilled syringe) once weekly for

919 48 weeks by subcutaneous administration in the abdomen or thigh.

920 **PEGASYS/COPEGUS Combination Therapy**

921 The recommended dose when used in combination with ribavirin is PEGASYS 180 µg sc
922 once weekly and COPEGUS 800 mg po daily given in two divided doses for a total of 48
923 weeks, regardless of genotype.

924 Since COPEGUS absorption increases when administered with a meal, patients are 925 advised to take COPEGUS with food.

926 Chronic Hepatitis B

927 **PEGASYS Monotherapy**

928 The recommended dose of PEGASYS monotherapy for hepatitis B is 180 μ g (1.0 mL 929 vial or 0.5 mL prefilled syringe) once weekly for 48 weeks by subcutaneous 930 administration in the abdomen or thigh.

931 **Dose Modifications**

932 If severe adverse reactions or laboratory abnormalities develop during combination
 933 COPEGUS/PEGASYS therapy, the dose should be modified or discontinued, if
 934 appropriate, until the adverse reactions abate. If intolerance persists after dose
 935 adjustment, COPEGUS/PEGASYS therapy should be discontinued.

936 **PEGASYS**

937 General

938 When dose modification is required for moderate to severe adverse reactions (clinical 939 and/or laboratory), initial dose reduction to 135 μ g (which is 0.75 mL for the vials or 940 adjustment to the corresponding graduation mark for the syringes) is generally adequate. 941 However, in some cases, dose reduction to 90 μ g (which is 0.5 mL for the vials or 942 adjustment to the corresponding graduation mark for the syringes) may be needed.

- Following improvement of the adverse reaction, re-escalation of the dose may be considered (see WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS).
- 945 Hematological

946 **Table 8 PEGASYS Hematological Dose Modification Guidelines**

Laboratory Values	Reduce PEGASYS Dose to:	Discontinue PEGASYS if:
ANC \geq 750/mm ³ ANC $<$ 750/mm ³	Maintain 180 μg Reduce to 135 μg	ANC <500/mm ³ , treatment should be suspended until ANC values return to more than 1000/mm ³ Reinstitute at 90 μg and monitor ANC
Platelet \geq 50,000/mm ³ Platelet $<$ 50,000/mm ³	Maintain 180 μg Reduce to 90 μg	Platelet count <25,000/mm ³

947 Psychiatric: Depression

948 949

Table 9Guidelines for Modification or Discontinuation of PEGASYSand for Scheduling Visits for Patients With Depression

Depression Severity	Initial Management (4-8 weeks)		Depression		
	Dose modification	Visit schedule	Remains stable	Improves	Worsens
Mild	No change	Evaluate once weekly by visit and/or phone	Continue weekly visit schedule	Resume normal visit schedule	(See moderate or severe depression)
Moderate	Decrease PEGASYS dose to 135 µg (in some cases dose reduction to 90 µg may be needed)	Evaluate once weekly (office visit at least every other week)	Consider psychiatric consultation. Continue reduced dosing	If symptoms improve and are stable for 4 weeks, may resume normal visit schedule. Continue reduced dosing or return to normal dose	(See severe depression)
Severe	Discontinue PEGASYS permanently	Obtain immediate psychiatric consultation	Psychiatric ther	apy necessary	

950 Renal Function

In patients with end-stage renal disease requiring hemodialysis, dose reduction to 135 μg
 PEGASYS is recommended. Signs and symptoms of interferon toxicity should be closely
 monitored.

954 Liver Function

If ALT increases are progressive despite dose reduction or accompanied by increased
bilirubin or evidence of hepatic decompensation, therapy should be immediately
discontinued.

958 In chronic hepatitis C patients with progressive ALT increases above baseline values, the 959 dose of PEGASYS should be reduced to 135 µg and more frequent monitoring of liver 960 function should be performed. After PEGASYS dose reduction or withholding, therapy 961 can be resumed after ALT flares subside.

962 In chronic hepatitis B patients with elevations in ALT (>5 x ULN), more frequent 963 monitoring of liver function should be performed and consideration should be given to 964 either reducing the dose of PEGASYS to 135 μ g or temporarily discontinuing treatment. 965 After PEGASYS dose reduction or withholding, therapy can be resumed after ALT flares 966 subside.

In patients with persistent, severe (ALT >10 times above the upper limit of normal)
 hepatitis B flares, consideration should be given to discontinuation of treatment.

969 COPEGUS

970 **Ta**

Table 10 COPEGUS Dosage Modification Guidelines

Laboratory Values	Reduce Only COPEGUS Dose to 600 mg/day* if:	Discontinue COPEGUS if:
Hemoglobin in patients with no cardiac disease	<10 g/dL	<8.5 g/dL
Hemoglobin in patients with history of stable cardiac disease	≥2 g/dL decrease in hemoglobin during any 4 week period treatment	<12 g/dL despite 4 weeks at reduced dose

* One 200 mg tablet in the morning and two 200 mg tablets in the evening.

972

973 Once COPEGUS has been withheld due to a laboratory abnormality or clinical 974 manifestation, an attempt may be made to restart COPEGUS at 600 mg daily and further 975 increase the dose to 800 mg daily depending upon the physician's judgment. However, it 976 is not recommended that COPEGUS be increased to the original dose (1000 mg or 977 1200 mg).

978 Renal Impairment

979 COPEGUS should not be used in patients with creatinine clearance <50 mL/min (see
 980 CLINICAL PHARMACOLOGY, WARNINGS and COPEGUS Package Insert).

981 HOW SUPPLIED

982 Single Dose Vial

Each PEGASYS (peginterferon alfa-2a) 180 µg single use, clear glass vial provides
1.0 mL containing 180 µg peginterferon alfa-2a for sc injection. Each package contains 1
vial (NDC 0004-0350-09).

986 Vials Monthly Convenience Pack

Four vials of PEGASYS (peginterferon alfa-2a), 180 µg single use, clear glass vials, in a
box with 4 syringes and 8 alcohol swabs (NDC 0004-0350-39). Each syringe is a 1 mL
(1 cc) volume syringe supplied with a 27-gauge, ¹/₂-inch needle with needle-stick
protection device.

991 **Prefilled Syringes Monthly Convenience Pack**

992 Four prefilled syringes of PEGASYS (peginterferon alfa-2a), 180 μ g single use, 993 graduated, clear glass prefilled syringes, in a box with 4 needles and 4 alcohol swabs 994 (NDC 0004-0352-39). Each syringe is a 0.5 mL ($\frac{1}{2}$ cc) volume syringe supplied with a 995 27-gauge, $\frac{1}{2}$ -inch needle with needle-stick protection device.

996 Storage

Store in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Protect
from light. Vials and prefilled syringes are for single use only. Discard any unused
portion.

1000 REBETRON[®], REBETROL[®], and INTRON[®] are registered trademarks of Schering
 1001 Corporation.

1002 Revised: May 2005

1004

1003 MEDICATION GUIDE

PEGASYS®

1005 (peginterferon alfa-2a)

1006 Before you start taking PEGASYS (PEG-ah-sis), alone or in combination with 1007 COPEGUS[®] (Co-PEG-UHS), please read this Medication Guide carefully. Read this 1008 Medication Guide each time you refill your prescription in case new information has 1009 been added and make sure the pharmacist has given you the medicine your healthcare 1010 provider prescribed for you. Reading the information in this Medication Guide does not 1011 take the place of talking with your healthcare provider.

1012 If you are taking PEGASYS in combination with COPEGUS, you should also read the
 1013 Medication Guide for COPEGUS (ribavirin, USP) Tablets.

1014 What is the most important information I should know about PEGASYS 1015 therapy?

PEGASYS, taken alone or in combination with COPEGUS, is a treatment for some 1016 1017 people who are infected with hepatitis C virus. PEGASYS taken alone is a treatment for 1018 some people who are infected with the hepatitis B virus. However, PEGASYS and 1019 COPEGUS can have serious side effects that may cause death in rare cases. Before 1020 starting PEGASYS therapy, you should talk with your healthcare provider about the 1021 possible benefits and the possible side effects of treatment, to decide if either of these 1022 treatments is right for you. If you begin treatment you will need to see your healthcare provider regularly for examinations and blood tests to make sure your treatment is 1023 1024 working and to check for side effects.

1025 The most serious possible side effects of PEGASYS taken alone or in combination with 1026 COPEGUS include:

1027 **Risks to Pregnancy:**

1028 Taking PEGASYS in combination with COPEGUS tablets can cause death, serious 1029 birth defects or other harm to your unborn child. Therefore, if you are pregnant or 1030 your partner is pregnant or plans to become pregnant, do not take 1031 PEGASYS/COPEGUS combination therapy. Female patients and female partners 1032 of male patients being treated with PEGASYS/COPEGUS combination therapy 1033 must not become pregnant during treatment and for 6 months after treatment has 1034 stopped. During this time, you must have pregnancy tests that show you are not 1035 pregnant. You must also use two effective forms of birth control during therapy and 1036 for 6 months after stopping therapy. Male patients should use a condom with 1037 spermicide as one of the two forms. You must use birth control even if you believe that 1038 you are not fertile or that your fertility is low. You should talk to your healthcare provider 1039 about birth control for you and your partner.

1040 If you are pregnant, you or your male partner must not take PEGASYS/COPEGUS
1041 combination therapy. If you or your partner are being treated and you become
1042 pregnant either during treatment or within 6 months of stopping treatment, call
1043 your healthcare provider right away.

1044 If you or a female sexual partner becomes pregnant, you should tell your healthcare 1045 provider. There is a Ribavirin Pregnancy Registry that collects information about 1046 pregnancy outcomes of female patients and female partners of male patients exposed to 1047 ribavirin. You or your healthcare provider are encouraged to contact the Registry at 1-1048 800-593-2214.

1049 Mental health problems:

PEGASYS may cause some patients to develop mood or behavioral problems. Signs of these problems include irritability (getting easily upset), depression (feeling low, feeling bad about yourself or feeling hopeless), and anxiety. Some patients may have aggressive behavior. Some patients may develop thoughts about ending their lives (suicidal thoughts) and may attempt to do so. A few patients have even ended their lives. Former drug addicts may fall back into drug addiction or overdose. You must tell your healthcare

1056 provider if you are being treated for a mental illness or have a history of mental illness or

- 1057 if you are or have ever been addicted to drugs or alcohol. Call your healthcare provider
- 1058 immediately if you develop any of these problems while on PEGASYS treatment.

1059 Blood problems:

Many patients taking PEGASYS have had a drop in the number of their white blood cells
and their platelets. If the numbers of these blood cells are too low, you could be at risk for
serious infections or bleeding.

1063 COPEGUS causes a decrease in the number of your red blood cells (anemia). This can be
1064 dangerous, especially for patients who already have heart or circulatory (cardiovascular)
1065 problems. If you have or have ever had any cardiovascular problems, talk with your
1066 healthcare provider before taking the combination of PEGASYS and COPEGUS.

1067 Liver Problems:

Infrequently, some patients with hepatitis C and liver scarring can develop sudden severe
worsening (failure) of their liver disease while taking PEGASYS. Patients infected with
both the hepatitis C virus and HIV can have an increased chance of having liver failure
during PEGASYS treatment.

1072 Some patients taking PEGASYS for hepatitis B have had a rise in a blood test that 1073 measures liver inflammation. If you have a rise in this blood test, your liver may need to 1074 be watched more closely with additional blood tests.

1075 Infections:

Some patients taking interferon have had serious infections. Sometimes these infections have been fatal. If you develop a fever that does not go away or gets higher, call your healthcare provider right away. Your healthcare provider will need to examine you to rule out your having a serious infection.

1080 Body organ problems:

Some patients may experience lung problems (such as difficulty breathing or pneumonia)and eye problems that can cause blurred vision or loss of your vision.

1083 Call your healthcare provider immediately if you develop any of these1084 conditions:

- You become very depressed or think about suicide
- You have severe chest pain
- You have trouble breathing
- 1088 You have a change in your vision
- 1089 You become pregnant
- 1090 You notice unusual bleeding or bruising
- You have psoriasis (a skin disease) and it gets worse while taking PEGASYS
- High fever or a fever that does not go away
- You have severe stomach pain or lower back pain
- **Bloody diarrhea**

1085

1086

1087

1096 For more information on possible side effects with PEGASYS therapy, alone or in 1097 combination with COPEGUS, please read the section on **"What are the possible side** 1098 effects of PEGASYS, and PEGASYS taken with COPEGUS?" in this Medication 1099 Guide. You should also read the Medication Guide for COPEGUS tablets if you are 1100 taking that medicine with PEGASYS.

1101 What is PEGASYS?

PEGASYS is a drug used to treat adults who have a lasting (chronic) infection with hepatitis C virus or hepatitis B virus and who show signs that the virus is damaging the liver. Patients with hepatitis have the virus in their blood and in their liver. PEGASYS reduces the amount of hepatitis C virus in the body and helps the body's immune system fight the virus. The drug COPEGUS are tablets that may be taken with PEGASYS to help fight the virus infection. Do not take COPEGUS by itself.

1108 In some patients that have received PEGASYS treatment for approximately one year to 1109 treat hepatitis C, the amount of the hepatitis virus in the body was decreased to a level so 1110 low that it could not be measured by blood tests. After 3 months of therapy, your 1111 healthcare provider may ask you to have a blood test to help determine how you are 1112 responding to your treatment.

1113 It is not known if PEGASYS, used alone or in combination with COPEGUS, can cure
1114 hepatitis (permanently eliminate the virus) or if it can prevent liver failure or liver cancer
1115 that is caused by hepatitis infection.

1116 It is also not known if PEGASYS, alone or in combination with COPEGUS, will prevent1117 one infected person from infecting another person with hepatitis.

1118 Who should not take PEGASYS, or PEGASYS with COPEGUS?

- 1119 Do not take PEGASYS or PEGASYS/COPEGUS therapy if you:
- are pregnant, planning to get pregnant during treatment or during the 6 months after
 treatment or breast-feeding
- are a male patient with a female sexual partner who is pregnant or plans to become
 pregnant at any time while you are being treated with COPEGUS or during the 6
 months after your treatment has ended
- have hepatitis caused by your immune system attacking your liver (autoimmune hepatitis)
- 1127 have unstable or severe liver disease
- had an allergic reaction to another alpha interferon or are allergic to any of the
 ingredients in PEGASYS or COPEGUS tablets
- Do not take PEGASYS, alone or in combination with COPEGUS, if you have
 abnormal red blood cells such as sickle-cell anemia or thalassemia major.
- 1132
- 1133 If you have ever had any of the following conditions or serious medical
 1134 problems, tell your healthcare provider before you start taking PEGASYS:
- History of or current severe mental illness (such as depression or anxiety)
- History of drug or alcohol addiction or abuse

- History of heart disease or previous heart attack
- 1138 History of cancer
- Autoimmune disease (where the body's immune system attacks the body's own cells), such as psoriasis (a skin disease), systemic lupus erythematosus, rheumatoid arthritis
- 1142 Kidney problems
- Blood disorders
- You take a medicine called theophylline
- 1145 Diabetes (high blood sugar)
- Problems with the thyroid gland
- 1147 Liver problems, other than hepatitis C or hepatitis B
- Colitis (an inflammation of the bowels)
- 1149

1150 You should tell your healthcare provider if you are taking or planning to take other

- 1151 prescription or nonprescription medicines or vitamin and mineral supplements or herbal
- 1152 medicines.

1153 If you have any questions about your health condition or about taking PEGASYS alone 1154 or in combination with COPEGUS, you should talk to your healthcare provider.

1155 How should I take PEGASYS, or PEGASYS with COPEGUS?

1156 PEGASYS is given by injection under the skin (subcutaneous injection). PEGASYS comes in two different forms (a liquid in a single use vial and a liquid in a prefilled 1157 syringe). Your healthcare provider will determine which is best for you. Your healthcare 1158 1159 provider will also decide whether you will take PEGASYS alone or with COPEGUS. Your dose of PEGASYS is given as a single injection once per week. At some point, your 1160 1161 healthcare provider may change your dose of PEGASYS or COPEGUS. Do not change your dose unless your healthcare provider tells you to change it. It is important that you 1162 1163 take PEGASYS and COPEGUS exactly as your healthcare provider tells you. Once you start treatment with PEGASYS, do not switch to another brand of interferon without 1164 1165 talking to your healthcare provider. Other interferons may not have the same effect on the 1166 treatment of your disease. Switching brands will also require a change in your dose.

1167 Take your prescribed dose of PEGASYS once a week, on the same day of each week and 1168 at approximately the same time. Your total dose of COPEGUS tablets should be divided 1169 so you take it twice a day with food (breakfast and dinner). Taking half your dose of 1170 COPEGUS in the morning and the other half at night will keep the medicine in your body 1171 at a steady level. Do not take more than your prescribed dose of PEGASYS or 1172 COPEGUS. Be sure to read the Medication Guide for COPEGUS (ribavirin, USP) 1173 for complete instructions on how to take the COPEGUS tablets.

1174 Your healthcare provider will train you and/or the person that will be giving you the 1175 PEGASYS injections on the proper way to give injections. Whether you give yourself the 1176 injection or another person gives the injection to you, it is important that you are 1177 comfortable with preparing and injecting a dose of PEGASYS, and you understand the 1178 instructions in "How do I inject PEGASYS?" At the end of this guide there are

1179 detailed instructions on how to prepare and give yourself an injection of PEGASYS 1180 using the form your healthcare provider has prescribed for you.

1181 If you miss a dose and you remember within 2 days of when you should have taken 1182 PEGASYS, give yourself an injection of PEGASYS as soon as you remember. Take your next dose on the day you would usually take it. If more than 2 days have passed, ask 1183 1184 your healthcare provider what you should do. If you miss a dose of COPEGUS, take the 1185 missed dose as soon as you remember during the same day. Do not take 2 doses too close 1186 together in time. If it is late in the day, wait until the next day and go back on schedule. Do not double the next dose. 1187

- 1188 If you take more than the prescribed amount of PEGASYS, call your healthcare provider 1189 right away. Your healthcare provider may want to examine you and take blood for 1190 testing.
- 1191 You must get regular blood tests to help your healthcare provider check how the treatment is working and to check for side effects. 1192

1193 What should I avoid while taking PEGASYS, or PEGASYS with COPEGUS?

- 1194 If you are pregnant do not start taking or continue taking COPEGUS in combination ٠ 1195 with PEGASYS. (See "What is the most important information I should know 1196 about PEGASYS therapy? Risks to Pregnancy".)
- Avoid becoming pregnant while taking PEGASYS, alone or in combination with 1197 • 1198 COPEGUS. PEGASYS, alone or in combination with COPEGUS, may harm your 1199 unborn child (death or serious birth defects) or cause you to lose your baby
- 1200 (miscarry). (See "What is the most important information I should know about
- 1201 **PEGASYS therapy? Risks to Pregnancy".)**
- 1202 Do not breast-feed your baby while on PEGASYS, alone or in combination with 1203 COPEGUS.

1204 What are the possible side effects of PEGASYS, and PEGASYS taken with 1205 **COPEGUS?**

- Possible, serious side effects include: 1206
- 1207 Risk to pregnancy, mental health problems including suicidal thoughts, blood ٠ 1208 problems, infections, and body organ problems: See "What is the most important information I should know about PEGASYS therapy?" in this Medication Guide. 1209
- 1210 • Autoimmune problems: Some patients may develop a disease where the body's own 1211 immune system begins to attack itself (autoimmune disease) while on PEGASYS therapy. These diseases can include psoriasis or thyroid problems. In some patients 1212 1213 who already have an autoimmune disease, the disease may worsen while on 1214 PEGASYS therapy.
- Heart problems: PEGASYS may cause some patients to experience chest pain, and 1215 • 1216 very rarely a heart attack. Patients who already have heart disease could be at greatest 1217 risk. Tell your healthcare provider if you have or have had a heart problem in the past.
- 1218 Liver Problems: Some patients may develop worsening of liver function. Some of • 1219 the symptoms may include stomach bloating, confusion, brown urine, and yellow eyes. Tell your healthcare provider immediately if any of these symptoms occur. 1220

1221 1222	Common, but less serious, side effects include:
1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239	 Flu-like symptoms: Most patients who take PEGASYS have flu-like symptoms that usually lessen after the first few weeks of treatment. Flu-like symptoms may include fever, chills, muscle aches, joint pain, and headaches. Taking pain and fever reducers such as acetaminophen or ibuprofen before you take PEGASYS can help with these symptoms. You can also try taking PEGASYS at night. You may be able to sleep through the symptoms. Extreme fatigue (tiredness): Many patients may become extremely tired while on PEGASYS therapy. Upset stomach: Nausea, taste changes, diarrhea, and loss of appetite occur commonly. Blood sugar problems: Some patients may develop a problem with the way their body controls their blood sugar and may develop the diabetes. Skin reactions: Some patients may develop rash, dry or itchy skin, and redness and swelling at the site of injection. Hair thinning: Temporary hair loss is not uncommon during treatment with PEGASYS. Trouble sleeping
1240 1241	These are not all of the side effects of PEGASYS, and PEGASYS taken with COPEGUS. Your healthcare provider or pharmacist can give you a more complete list.
1242 1243	Talk to your healthcare provider if you are worried about side effects or find them very bothersome.
1244 1245 1246 1247 1248 1249 1250	General advice about prescription medicines Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you have any concerns or questions about PEGASYS, contact your healthcare provider. Do not use PEGASYS for a condition or person other than that for which it is prescribed. If you want to know more about PEGASYS, your healthcare provider or pharmacist will be able to provide you with detailed information that is written for health- care providers.
1251 1252	If you are taking COPEGUS (ribavirin, USP) in combination with PEGASYS, also read the Medication Guide supplied with that medicine.
1253	Keep this and all drugs out of the reach of children.
1254	This Medication Guide has been approved by the US Food and Drug Administration.

1255 Revised: May 2005

PEGASYS® (peginterferon alfa-2a)

1256Medication Guide Appendix: Instructions for Preparing and Giving a Dose with a1257PEGASYS® Prefilled Syringe

1258 How should I store PEGASYS Prefilled Syringes?

PEGASYS must be stored in the refrigerator at a temperature of 2°C to 8°C (36°F to 46°F). Do not leave PEGASYS outside of the refrigerator for more than 24 hours. Do not freeze PEGASYS. Keeping PEGASYS at temperatures outside the recommended range

- 1262 can destroy the medicine.
- 1263 Each PEGASYS prefilled syringe can only be used once. Discard after use.
- 1264 Do not shake the prefilled syringe of PEGASYS. If PEGASYS is shaken too hard, it will1265 not work properly.
- 1266 Protect PEGASYS from light during storage.

1267 Keep this and all other medicines out of the reach of children.

1268 How do I prepare and inject PEGASYS?

You should read through all of these directions and ask your healthcare provider for help
if you have any questions before trying to give yourself an injection. It is important to
follow these directions carefully. Talk to your healthcare provider if you have any
questions about PEGASYS.

1273 Your healthcare provider may not want you to take all the medicine that comes in the 1274 prefilled syringe. To appropriately administer the dose that your healthcare provider tells 1275 you to take, you may have to get rid of some of the medicine before injecting the 1276 medicine.

1277 If you ever switch between using prefilled syringes and vials, talk to your healthcare 1278 provider about how much PEGASYS to use. Equal volumes of liquid from the prefilled 1279 syringes and the vials DO NOT contain the same amount of PEGASYS. If you switch 1280 between prefilled syringes and vials, you will have to adjust the volume of liquid that you 1281 use to give your injection. If you do not adjust this, you could accidentally take too much 1282 or too little of your medicine.

1283 If you are giving this injection to someone else, a healthcare provider must teach you how 1284 to avoid needle sticks. Being stuck by a used needle can pass diseases on to you.

1285 The prefilled syringes are used for injecting PEGASYS under the surface of the skin 1286 (subcutaneous).

1287

- 1288 1. Collect all the materials you will need before you start to give the injection:
- 1289


•

- 1290 1291
- 1292 1293
- inner carton holding the PEGASYS prefilled syringe


One PEGASYS prefilled syringe Monthly Convenience Pack containing an

- A puncture-resistant container for cleaning up when you are finished
- 1294 2. Open the convenience pack and look at the contents.

1295 1296 1297	 Each convenience pack has everything you need for the PEGASYS injection. 4 single use syringes filled with medicine (should be colorless to light yellow)
1298	- four 27-gauge, ¹ / ₂ -inch needles with needle-stick protection device
1299	 4 alcohol swabs
1300 1301	 Do not use PEGASYS if: the medicine is cloudy
1302	 the medicine has particles floating in it
1303	 the medicine is any color besides colorless to light yellow
1304	 the expiration date has passed
1305 1306 1307	3. Warm the refrigerated medicine by gently rolling it in the palms of your hands for about one minute. Do not shake.
1308	4. Wash your hands with soap and warm water to prevent infection.
1309 1310 1311 1312 1313	 5. Attachment of the needle to the PEGASYS prefilled syringe: Remove the needle from its package. Do not remove the needle shield yet. Keep the needle covered until just before you give the injection. Remove and discard the rubber cap from the tip of the syringe barrel.
1314	
1315 1316 1317	Put the needle onto the end of the syringe barrel so it fits tightly.Here is a picture of the assembled syringe:
1318	U - ·
1319 1320	• Keep the syringe in a horizontal position until ready for use.
1321	• If you need to set the syringe down, make sure the plastic shield covers the
1322 1323	needle. Never let the needle touch any surface.



• Pick a place on your stomach or thigh (see the picture below). Avoid your navel and waistline. You should use a different place each time you give yourself an injection.



1330

1325

1326

1327

1328 1329

- 1331 7. Prepare your skin for the injection.
- 1332 1333


• To minimize the discomfort from injections, you may want to gently tap the area where you plan to give yourself an injection.

• Clean the area using the alcohol pad. Let the skin dry for 10 seconds.

1334 1335

1336 8. Uncover the needle.

Remove the plastic safety shield covering the needle. Do not remove the
orange cap that is attached to the end of the syringe and above the needle that
is the needle-stick protection device.




13401341 9. Remove air bubbles from the syringe.

- Hold the syringe with the needle pointing up to the ceiling.
- Using your thumb and finger, tap the syringe to bring air bubbles to the top.
- Press the plunger in slightly to push air bubbles out of the syringe.
- Your healthcare provider may not want you to take all the medicine that comes in the prefilled syringe.
- To appropriately administer the dose that your healthcare provider tells you to take, you may have to get rid of some of the medicine before injecting the medicine.
- The syringe has markings for 180 mcg, 135 mcg, and 90 mcg. Your healthcare provider will tell you which mark to use.
- 1352

1342

1343


1344



1355

 Once you know which mark to use, slowly and carefully press on the plunger rod of the syringe to push out medicine from the syringe. Keep pressing until the edge of the plunger stopper reaches the right mark on the side of the syringe.

- Do not decrease or increase your dose of PEGASYS unless your healthcare
 provider tells you to.
- 1362
- 1363 10. Give the injection of PEGASYS.
- 1364
- Position the point of the needle (the bevel) so it is facing up.



- 1365
- Pinch a fold of skin on your stomach or thigh firmly with your thumb and forefinger.



- 1368
- Hold the syringe like a pencil at a 45° to 90° angle to your skin. In one quick motion, insert the needle as far as it will go into the pinched area of skin. Pull the plunger of the syringe back very slightly. If blood comes into the syringe, the needle has entered a blood vessel. Do not inject. Withdraw the needle and discard the syringe as outlined in step 11. Repeat the above steps with a new prefilled syringe and prepare a new site.
- If no blood appears, release your skin and slowly push the plunger all the way down so that you get all of your medicine.



- 1377
- 1378 1379
- Wipe the area with an alcohol swab.

Pull out the needle at same angle you put it in.

- 1380
- 1381 11. For safety reasons, before you dispose of the syringe and needle, place the free end of
 the orange cap on a flat surface and push down on it until it clicks and covers over the
 needle. Always place used syringes and needles in a puncture-resistant container

immediately after use and never reuse them. Keep your disposal container out of thereach of children.

1386 How should I dispose of materials used to inject PEGASYS?

1387 There may be special state and local laws for disposal of used needles and syringes. Your 1388 healthcare provider or pharmacist should provide you with instructions on how to

- 1389 properly dispose of your used syringes and needles. Always follow these instructions.
- 1390 The instructions below should be used as a general guide for proper disposal:
- The needles and syringes should never be reused.
- Place all used needles and syringes in a puncture-proof disposable container that is available through your pharmacy or healthcare provider (Sharp's container).
- DO NOT use glass or clear plastic containers for disposal of needles and syringes.
- Dispose of the full container as instructed by your healthcare provider or pharmacist.

1396 1397 DO NOT throw the container in your household trash. DO NOT recycle. Keep the 1398 container out of the reach of children.

1399 Appendix revision date: January 2004

Medication Guide Appendix: Instructions for Preparing and Giving a Dose with a PEGASYS[®] Vial

1402 How should I store PEGASYS vials?

PEGASYS must be stored in the refrigerator at a temperature of 2°C to 8°C (36°F to
46°F). Do not leave PEGASYS outside of the refrigerator for more than 24 hours. Do not
freeze PEGASYS. Keeping PEGASYS at temperatures outside the recommended range

1406 can destroy the medicine.

- 1407 Each PEGASYS vial can only be used once. Discard after use.
- Do not shake the vial of PEGASYS. If PEGASYS is shaken too hard, it will not workproperly.
- 1410 Protect PEGASYS from light during storage.
- 1411 Keep this and all other medicines out of the reach of children.

1412 How do I inject PEGASYS?

The following instructions will help you learn how to measure your dose and give yourself an injection of PEGASYS. You should read through all of these directions and ask your healthcare provider for help if you have any questions before trying to give yourself an injection. It is important to follow these directions carefully. Talk to your healthcare provider if you have any questions about PEGASYS.

1418 If you are giving an injection to someone else, a healthcare provider must teach you how 1419 to avoid needle sticks. Being stuck by a used needle can pass diseases on to you.

- 1420 1. Collect all the materials you will need before you start to give the injection:
- One vial of PEGASYS

	PEGASYS [°] (peginterferon alfa-2a)
1422 1423 1424 1425 1426 1427	 One syringe and needle Several alcohol pads A puncture-resistant container to dispose of the needle and syringe when you are finished If you have received the PEGASYS Convenience Pack, it includes PEGASYS, safety
1428	syringes and needles with a needle-stick protection device attached, and alcohol swabs.
1429 1430 1431 1432 1433	 2. Check the date on the carton the PEGASYS comes in and make sure the expiration date has not passed, then remove a vial from the package and look at the medicine. Do not use PEGASYS if: the medicine is cloudy
1434	- the medicine has particles floating in it
1435	- the medicine is any color besides colorless to light yellow
1436	 the expiration date has passed
1437 1438 1439	3. Warm the refrigerated medicine by gently rolling it in the palms of your hands for about one minute. Do not shake.
1440	4. Wash your hands with soap and warm water to prevent infection.
1441	5. Take the vial of PEGASYS and flip off the plastic top covering the vial opening, and

1442 clean the rubber stopper on the top of the vial with a different alcohol pad.




1443

1444

1445 If you are not sure how much medicine to use or which mark to use, STOP and call1446 your healthcare provider right away.

- 1447 6. Remove the needle and syringe from their packaging and attach the needle to the end1448 of the syringe.
- If you are using a syringe and needle supplied with the PEGASYS Convenience
 Pack, the needle is already attached to the syringe and it will have a needle-stick
 protection device attached. Remove the clear protective cap from the end of the
 needle. Do not remove the orange cap that is attached to the end of the syringe
 and above the needle that is the needle-stick protection device.
- 1454
- Pull the plunger back so the end of it is to the mark on the syringe barrel that
 matches the dose prescribed for you by your healthcare provider. This will pull air
 into the syringe barrel.



1458

- Push the needle through the center of the stopper on the vial.
- Slowly inject all the air from the syringe into the air space above the solution. Do not inject air into the fluid.



1462

1463	•	Keep the needle inside the vial and turn both upside down. Hold the vial and
1464		syringe straight up. Slowly pull back on the plunger until the medicine is in the
1465		syringe up to the mark that matches your dose. Make sure the needle tip always
1466		stays in the medicine (not in the air space above it).

1467

- When the medicine is up to the right mark on the syringe barrel, take the syringe and needle out of the rubber stopper on the vial.
- Keep the syringe pointing up until you are ready to use it.
- If you need to set the syringe down, make sure that you never let the needle touch any surface.
- 1473


1474 7. Remove air bubbles from the syringe.

- Hold the syringe with the needle pointing up to the ceiling.
- Using your thumb and finger, tap the syringe to bring air bubbles to top.
- Press the plunger in slightly to push air bubbles out of the syringe.
- 1478

1479 8. Decide where you will give the injection.

• Pick a place on your stomach or thigh (see the picture below). Avoid your navel

1481and waistline. You should use a different place each time you give yourself an1482injection.




1483

- 1484 9. Prepare your skin for the injection.
- To minimize the discomfort from injections, you may want to gently tap the area
 where you plan to give yourself an injection.
- Clean the area using an alcohol pad. Let the skin dry for 10 seconds.
- 1488

1491

- 1489 10. Give the injection of PEGASYS.
- Position the point of the needle (the bevel) so it is facing up.



- Pinch a fold of skin on your stomach or thigh firmly between your thumb and forefinger.
- 1494 1495

Alle I

1496

- Hold the syringe like a pencil at a 45° to 90° angle to your skin. In one quick motion, insert the needle as far as it will go into the pinched area of skin. Pull the plunger of the syringe back very slightly. If blood comes into the syringe, the needle has entered a blood vessel. Do not inject. Withdraw the needle and discard the syringe as outlined in step 11. Repeat the above steps with a new vial and syringe and prepare a new site.
- If no blood appears, release your skin and slowly push the plunger all the way down so that you get all of your medicine.



1506 1507 Pull out the needle at same angle you put it in. Wipe the area with an alcohol pad. 1508 1509 11. For safety reasons, always place used syringes and needles in a puncture-resistant 1510 container immediately after use and never reuse them. 1511 • If you are using a syringe with a needle-stick protection device, before you 1512 dispose of the syringe and needle, place the free end of the orange cap on a flat 1513 1514 • •

- surface and push down on it until it clicks and covers over the needle. How should I dispose of materials used to inject PEGASYS?
- 1515 There may be special state and local laws for disposal of used needles and syringes. Your 1516 healthcare provider or pharmacist should provide you with instructions on how to 1517 properly dispose of your used syringes and needles. Always follow these instructions.
- 1518 The instructions below should be used as a general guide for proper disposal:
- 1519 The needles and syringes should never be reused.
- 1520 Place all used needles and syringes in a puncture-proof disposable container that is 1521 available through your pharmacy or healthcare provider (Sharp's container).
- 1522 DO NOT use glass or clear plastic containers for disposal of needles and syringes. •
- 1523 Dispose of the full container as instructed by your healthcare provider or pharmacist.
- 1524

1525 DO NOT throw the container in your household trash. DO NOT recycle. Keep the 1526 container out of the reach of children.

1527 Appendix revision date: January 2004



Hoffmann-La Roche Inc. 340 Kingsland Street Nutley, New Jersey 07110-1199

- 1528
- 1529 U.S. Govt. Lic. No. 0136
- 1530 27898881
- 1531 Copyright© 2003-2005 by Hoffmann-La Roche Inc. All rights reserved.